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ABSTRACT 
 
Photodynamic therapy (PDT) is a very attractive modality of cancer treatment 
especially in combination with other therapies. It is generally acknowledged that 
the principal cytotoxic effects of PDT is mediated by the production of reactive 
Oxygen species that directly damage sub-cellular components including 
membranes and proteins.  
It has been shown that UPP system plays a pivotal role in the breakdown of the 
proteins that come unfolded in response to oxidative stress. To elucidate the role 
of UPP system in response to ROS-mediated damage, Photofrin-preloaded H1299 
and A549 (respectively p53-/- and p53+/+) were irradiated with halogen lamp 
equipped with bandpass filter using purposely sub-lethal dose (0.54 J/cm2). 
We have shown that the photodynamic treatment leads to a reversible decrease in 
proteasome activity, depending on ROS production, and to an increase in the 
accumulation of ubiquitinated proteins in both cell lines. PDT also resulted in an 
increase in the half life of various intracellular proteasome substrates as IκB and 
p27. We have also observed that the proteasome inhibition induces, 6 hours after 
the treatment, a significant accumulation of the cells in G2 phase. In these 
conditions, this alteration of cell cycle profile of both cell lines was reverted at 
longer time while a complete recovery of clonogenic survival.  
Considering that the prolongation of proteasome inhibition leads to cell death, we 
submitted the cells to a second photodynamic treatment during the proteasome 
activity lag phase. As expected, the second treatment prolonged this stall.  
Since it has been demonstrated, that Aspirin may cause a block of proteasome 
activity with an undefined mechanism, we have investigated the possible 
implications for therapy deriving from a combined use of PDT with this non toxic 
drug. In our system we could demonstrate that the block of the proteasome 
activity upon Aspirin treatment, was concomitant with an accumulation of cells in 
the G2 phase without apparent activation of apoptosis response and with 
restoration of their capacity to proliferate. 
In order to inhibit the recovery of the clonogenic potential observed after single 
treatments (with PDT or Aspirin) we decided to test if the combination of the two 
treatment might have an additive effect, so favouring apoptotic response versus 
the recovery. It has been observed that the mode of administration of treatments 
(PDT followed by Aspirin or Aspirin followed by PDT) may determine the 
proteasomal activity. Indeed, an effective and prolonged stall is obtained only 
upon administration of Aspirin to cells previously submitted to photodynamic 
treatment. We could demonstrate that with this particular modality of treatment 
Aspirin sustains the PDT-dependent G2 accumulation and concomitantly causes a 
decrease of clonogenic survival.  
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1. INTRODUCTION 
 
1.1 Photodynamic therapy  
Photodynamic therapy (PDT) is a minimally invasive therapeutic modality 
approved for treatment of many diffused human diseases, including macular 
degeneration, several dermatological disorders and cancer. Nowadays, PDT is 
finding increasing application for the treatment of lung, oesophageal, 
gynaecological, head and neck tumours. In particular PDT is considered the 
therapeutics treatment of choice of some precancerous lesions as Barrett’s 
oesophagus, non-melanoma skin cancers and some forms of advanced cancers not 
otherwise easy to treat.  
To now, PDT represents a very attractive modality of cancer treatment specially 
in combination with other conventional therapies as radio, immuno or chemo-
therapy. Possibly this combined approach might consents the reduction of the 
drug dose and the side effects preserving the overall efficacy.   
Historically, light has been used as therapy for more than three thousand 
years (Jain et al. 2002) but only at the end of the nineteenth century Niels Finsen 
used the word “phototherapy” to indicate the treatment of  cutaneous tuberculosis 
with ultraviolet light (Ackroyd et al. 2001). The principle of photodynamic 
therapy (PDT) was first proposed about 100 years ago when researchers observed 
that a combination of light and certain chemicals could induce tissue-damage. In 
1900 J. Prime, a neurologist, found that epilepsy patients who were treated with 
oral eosin developed dermatitis in sun-exposed areas. Later von Tappeiner and 
Jesionek treated skin tumours with eosin plus white light and demonstrated that 
this combination caused cell death. About thirty years after, Lipson and Baldes 
reported that the preparation of a non-toxic haematoporphyrin derivative (HPD) 
appeared to have a particular propensity to accumulate within neoplastic tissues. 
They, in fact, observed that injection of crude preparations of HPD led to 
fluorescence of neoplastic lesions visualized during surgery (Huettner et al. 2000). 
However, the clinical utility of PDT for tumour removal has been realised only in 
the 70’s when Thomas Dougherty and co-workers showed that the topically 
administration of HPD and red light completely eradicated mammary and bladder 
tumour in mice.  
Following the preliminary successes in the animal models , PDT was used in the 
human trials. Dougherty et al. treated with HPD-PDT 25 patients  with a total of 
113 primary or secondary skin tumours. A complete response was observed in 98 
tumours, a partial response was observed in 13 tumours and 2 tumours were found 
to be treatment resistant (Dolmans et al. 2003).  
 
1.2 Mechanism of PDT action 
PDT is based on the systemic or local administration (by injection or by 
topical exposition to the skin) and the selective accumulation and/or retention of a 
photosensitizing agent (photosensitizer) in diseased tissue followed by irradiation 
with visible light of a wavelength matching the absorption spectrum of the 
photosensitizer.  
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Following the absorption of photons, the photosensitizer is promoted from its 
ground singlet to its excited singlet state, which, in turn, decays back to its ground 
state. Upon light activation, the photosensitizing agent transfers its excess energy 
to different substrates.  
This phenomenon causes oxidative damage at in the immediate vicinities of the 
site in which photosensitizer accumulate. Importantly, a fraction of the excited 
singlet state molecules is transformed via intersystem crossing into the relatively 
long-lived (micro-to milliseconds) excited triplet state, which can either form free 
radicals or radical ions by hydrogen atom extraction or electron transfer to 
biological substrates (such as membrane lipids), solvent molecules or oxygen.  
These radicals can interact with ground-state molecular oxygen to produce 
superoxide anion radicals, hydrogen peroxides and hydroxyl radicals. Such 
reaction is generally indicated as Type I reaction. Alternatively, from the excited 
triplet state the compound can transfer directly its energy to ground-state 
molecular Oxygen to form highly reactive singlet oxygen (ROS) (Fig. 1, Buytaert 
et al. 2007). Such reaction is generally indicated as Type II reaction. 
 
 
Photosensitizer
(ground state)
Photosensitizer
(excited state)
O2 O2
O2
Citotoxicity
Reaction type IIReaction type 1
Substrate
H
H
H
Citotoxicity
O2 O2
O2
Light
ROS
ROS
 
 
Figure 1: Mechanism of action of photodynamic therapy (PDT). PDT requires three 
elements: light, a photosensitizer and Oxygen. When the photosensitizer is exposed to specific 
wavelengths of light, it becomes activated from a ground to an excited state. As it returns to the 
ground state, it releases energy, which is transferred to Oxygen to generate ROS, such as singlet 
oxygen and free radicals, that mediate cellular toxicity. 
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Both these reactions occur simultaneously and while the ratio between them 
depends on the nature of the photosensitizer and the substrate molecules 
(Dougherty et al. 1998). Indeed, several direct and indirect evidences support a 
pivotal role for 1O2 in the molecular processes initiated by photo-activation 
(Niedre et al. 2002). 
Photodynamic action induces damage only in cells that are proximal to the 
site of the ROS production (and consequently of photosensitizer localization) 
whereas surrounding tissues are poorly damaged. This is due to the fact that in 
biological system the half-life of singlet Oxygen is very short <0.04 µs, and, 
therefore, its radius of the action is less than 0.02 µm. The ROS that are produced 
during PDT have been shown to destroy target tissue by multifactorial 
mechanisms. In the case that the absorption of the exciting photons by the 
photosensitizer is followed by fluorescence emission, this event can be exploited  
for diagnostic purposes (Berg et al. 2005). 
 
1.3 PDT’s effect on tumour 
It is now known that there are three main mechanisms by which PDT induces 
tumour destruction through direct ROS-mediated photodamage: a) direct cancer 
cell death b) destruction of the tumour-associate vasculature and c) possible 
activation of an immune response. The relative importance of each of these 
mechanisms on the tumour response has yet to be defined, although a combination 
of these processes. It is appears, however, that combination of all process is 
important in the long-term tumour control. 
The photo-damage depends on many different factors. In particular it may result 
significant different in extent and cellular effect depending on the nature and dose 
of the sensitizer, the extra-cellular and/or intracellular localization, the time 
interval between the administration of the drug and light exposure, the light Dose 
(the total energy of exposed light across a sectional area of irradiated spot), the 
Fluence Rate of the light (the radiant energy incident per second across a sectional 
area of irradiated spot) and the Oxygen availability.  
 
1.3.1 Direct tumour-cell killing 
It is known that the PDT may have a direct effect on cancer cells and causing 
in vivo a decrease of the number of the clonogenic tumour cells (Henderson et al. 
1985). Qualitatively, the photodynamic action may trigger apoptosis or may 
primer necrosis or autophagy. The balance between apoptosis and necrosis after 
PDT in vitro depends on several factors including the intracellular localization of 
photosensitizer and the light fluence (Oleinick  et al. 2002). 
The intracellular localization of photosensitizer depends on its chemical nature 
and this fact determines its sub-cellular distribution. The latter is finally 
responsible in ruling the cellular response to photodynamic damage (Noodt and al. 
1999).  
As already stated, the photo-generated singlet Oxygen, has a very short half-life 
and very limited diffusion capacity in biological systems. This implies that 
primary molecular targets of the photodynamic process must reside within few  
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nanometers from the dye. Generally, photoactive compounds that localize within 
mitochondria or ER promote apoptosis, within a certain threshold of oxidative 
stress, while activation of photosensitizer targeting either the plasma membrane or 
lysosomes can either delay or even block the apoptotic program predisposing the 
cells to necrosis (Oleinick et al. 2002). Therefore the localization of photoactive 
compounds depends also on the incubation time. In fact, several studies have 
demonstrated that the widely used photosensitizer Photofrin concentrates into 
different cellular compartments, according to incubation time. Photofrin 
accumulates in plasma membranes or cytoplasm upon brief incubation, and in the 
Golgi complex or RE upon prolonged incubation (Hsieh et al. 2003). 
Indeed, some studies have reported on the re-localization of certain 
photosensitizers after irradiation suggesting that, besides the primary site, 
photodamage can be directed to other subcellular locations (Kessel 2002 and 
Marchal et al. 2007).  
It is clear, the cellular response to PDT depends also on the light fluence. While 
apoptosis is the predominant mode of cell death when cells are photosensitized 
with low light doses, necrosis was observed at higher doses (Vantiegheman et al. 
1998).  
In recent time, a some papers have reported that sublethal photo-damage of a cell 
may trigger in its autophagy and promote cell survival (Buytaert et al. 2006). This 
is obtained by removing damaged organelles. Alternatively it may also promote 
cell death through excessive self-digestion or degradation of essential cellular 
constituents is generated (Gozuacik et al. 2004 and Tsujimoto et al. 2005).  
 
1.3.2 Vascular damage 
The viability of cancer cells depends on the amount of nutrients supplied by 
the blood vessels. In turn, formation and maintenance of blood vessels depend on 
growth factors produced by tumour or host cells (Carmeliet et al. 2000). Targeting 
the tumour vasculature is therefore one promising approach to cancer treatment.  
PDT also has an effect on the tumour vasculature, whereby illumination and ROS 
production cause the shutdown of vessels and subsequently deprive the tumour of 
nutrients  (Dolmans et al. 2002). It has been reported that PDT may induce 
vasculature collapse with consequent hypoxia of the neighbouring tissues and 
rapid thrombus formation in animal model. In particular, MV6401 
(pyropheophorbide derivative) - a new photosensitizer - caused a biphasic 
vascular response following PDT. The most rapid response was vasoconstriction. 
This initial phase was followed three hours later by the formation of thrombus. 
Interestingly enough, these vascular effects were associated with a delay in 
tumour growth. Different studies with other photosensitizers, such Photofrin also 
reported vascular constriction, thrombus formation and inhibition of tumour 
growth (Fingar et al. 1997). On the other hand, expression of vascular endothelial 
growth factor (VEGF) and cycloxygenase (COX-2) — both potent angiogenic 
factors — were up-regulated during PDT (Ferrario et al. 2002). These effects were 
presumably due to the ROS formation and secondary hypoxia that was induced by 
PDT. Although most of these observation have been reported in the past, further  
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studies are required to definitively establish the long-term effects of PDT on 
tumour vasculature. 
 
1.3.3 Immune response 
In contrast to most cancer treatments that are prevalently 
immunosuppressive, PDT may exert a pro-inflammatory action. In this regard, 
several studies have demonstrated that PDT causes acute inflammatory and 
immune responses like expression of heat shock proteins, invasion and leukocyte 
infiltration of the tumour. In addition, PDT appears to increase the presentation of 
tumour-derived antigen to T cells (Castano 2006). PDT causes attraction of host 
leukocytes, lymphocytes, and macrophages into treated tumour tissue, by up-
regulating the inflammatory cytokines interleukin (IL)-6 and IL-1 and by 
activating the neutrophil accumulation (Henderson et al. 1992; Korbelik 1996 and  
Gollnick et al. 1997).  
In such regard it is of remarkable interest the observation that following sub-lethal 
photodynamic treatment of MCF-7 cells, the levels of HSP70 mRNA were 
increased (Nonaka et al. 2004). It is now known that HSP70, released from 
necrotic tumour cells, are non only able to inhibit tumour cell death by apoptosis 
but also to promote the formation of stable complexes with cytoplasm tumour 
antigens. These antigens can then either be expressed at the cell surface or escape 
intact from dying necrotic cells to interact with antigen-presenting cells (APCs) 
and stimulate an antitumour response  (Castano et al. 2006). 
Extra cellular HSP70 binds to high affinity receptors on the surface of  APCs. 
This leads to the activation and maturation of dendritic cells, a process that 
enables the cross-presentation of peptide antigen cargo of HSP70 by the APCs to 
CD8 + cytotoxic T cells.  
The release of HSP-bound tumour antigens that can easily be taken up by APC 
from PDT–induced necrotic tumour cells, may explain the efficiency of PDT in 
stimulating an immune response against tumours (Ahmad et al. 2004).  
On the other hand, the evaluation of long term effects of Photofrin-PDT on 
tumour growth in normal Balb/C and immunodeficient mice showed that the 
tumour recurrence occurred more frequently in the immuno-compromised mice 
and that this effect was reversed by bone-marrow transplants from immuno-
competent Balb/C donors. These results suggest that, whereas the direct effects of 
PDT can destroy the bulk of the tumour, the immune response may result very 
helpful in eliminating the survived cells (Korbelik et al. 1996).  
Studies in this direction are actively going on to demonstrate such effect also in 
patients who received PDT.  
Finally, recent experiments reported that a extracts from Photofrin/PDT treated 
cells could be used to vaccinate mice against the development of further tumours. 
Also this observation agrees with the hypothesis of a strong induction of tumour-
specific immunity (Gollnick et al. 2002).  
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1.4 Photosensitezers  
The most ideal photosensitizer would be a chemically pure drug with 
preferential uptake in tumour, rapid clearance from surrounding normal tissue, 
less skin photosensitivity, capacity to absorb light at longer wavelengths (to 
facilitate tissue penetration of the light), and minimal toxicity in dark. 
In general, the photosensitizers used in human cancer therapy (including clinical 
trials) are intravenously infused but, in the case of patients with skin cancer, the 
topical application is an obvious alternative. The time between the injection and 
exposure to light may vary from drug to drug, according to the respective 
pharmacokinetic properties.  
Most photosensitizers approved for use in humans in selected cases belong to 
the class of porphyrins and chlorines and include porfimer sodium, m-THPC, 
meta-tetrahydroxyphenylchlorin, verteporfin, and benzoporphyrin derivative 
monoacid ring A. Another important class of photosensitizer largely employed in 
dermatology (i.e., actinic keratosis) includes 5-aminolevulinic acid, methyl and 
benzyl aminolevulinate. In table 1 are shown several photosensitizers used in 
clinical trials or at preclinical stages.   
 
ER, Nucleus, Golgi apparatus 790Cell lines.ICGIndocyanine Green
ER, Lysosomes550-590Cell linesHypericin
ER, Mitochondria650
700
Animal studies, cell lines.ALPcSnSulphonated aluminum
phthalocyanines
Photosensitizers used in preclinical cancer studies
Mitochondria~665Esophageal cancers. Preclinical 
studies.
HPPH 
Photochlor
2-[1-hexyloxyethyl]-2-
devinyl pyropheophorbide 
Mitochondria, Nucleus763Prostate (after radiation failure). 
Preclinical studies.
TookadPd-bact-pheophorbide
ER740Liver metastasis.  Preclinical 
studies.
SQN 400 
mTHPBC
[5,10,15,20]-tetrakis-m-
hydroxy phenyl-chlorin
Golgi apparatus, Plasma650
800
Head and neck, other. Preclinical 
studies.
PhotosensDisulphonate-Al-phtalo-
cyanine
Lysosomes, Endosomes664Early endobronchial carcinoma. 
Preclinical studies.
LaserphyrinMono-asparylchlorin e6 or 
Taloporfin Na, NPe6
Photosensitizers used in preclinical cancer studies and/or phase I-III clinical trials
Mitochondria, Cytosol, 
membranes
635Basal carcinoma, head and neck, 
gynaecological cancer.
Levulan5-ALA
Mitochondria, ER~690Basal-cell carcinomaVerteporfinBPD-MA, Verteporfin
ER, Mitochondria~650Head and neck, (prostate, 
pancreas).
Foscanm-THPC
Golgi apparatus, Plasma 
membrane,
ER
~630Cervix, advanced and early lung, 
esophageal, bladder, superficial 
gastric, brain cancers. 
PhotofrinPorfimer Na
Cellular localization? (nm)Major Reported UsesTrade namePhotosensitizer
Photosensitizers used in clinical and preclinical cancer studies 
 
 
Table 1: The table show the most photosensitizers used in clinical trials or at preclinical 
stages and their sub-cellular localization (modified by Palumbo 2007). 
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1.5 Photofrin® 
The development of Photofrin®, approved in 1993 in Canada for the treatment 
of bladder cancer, was a breakthrough in PDT research. Today this 
photosensitizer holds the largest number of approvals for clinical use.  
In particular, Porfimer sodium is the most commonly photosensitizer used in 
Europe for the treatment of advanced stage lung cancer, in Japan for early-stage 
oesophageal, gastric and cervical cancer and in the United States for advanced 
oesophageal cancer (Almeida et al. 2004 and Dougherty 2002) 
Photofrin® is a haematoporphyrin derivative. This is typically < 50% 
monomeric/dimeric porphyrins and > 50% oligomeric material. The latter fraction 
(porfimer sodium) has been partly purified in the commercial development of 
Porfimer sodium or Photofrin® (Fig. 2), which has been reported to be ~90% 
oligomeric material. 
 
 
 
Figura 2: Photofrin®, the most popular photosensitizer used in PDT. Photofrin is a 
haematoporphyrin derivative. This is typically < 50% monomeric/dimeric porphyrins and > 50% 
oligomeric material. The latter fraction (porfimer sodium) has been partly purified in the 
commercial development of Porfimer sodium or Photofrin®  which has been reported to be ~90% 
oligomeric material. 
 
 
The advantages offered by Photofrin® include the possibility of using minimal 
drug and light doses (respectively 2.0 mg/kg and to 50 until 150 J/cm2) and the 
good clearance from surrounding normal tissue (MÄkvy et al.1998). The drug, 
moreover, is not toxic and can be administered repeatedly, without consequences 
for the neoplastic patient.  
Photofrin®, however, causes long-lasting cutaneous photosensitivity, as it is 
absorbed by the skin. For this reason, patients who have been treated with 
Porfimer sodium have to avoid sunlight for long time (Sibata et al. 2001). 
However, there are some drawbacks with this photosensitizer because it is a 
mix of about 60 different compounds and therefore it is difficult to reproduce its  
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composition. In addition, Photofrin® is activated at λ 630 nm. At this wavelength 
the light scarcely penetrates human tissues and so is not suitable for non-
superficial cancers.   
Although, these latter observations have prompted researcher to discover and 
assay new photosensitizers, Photofrin® remains the most popular in PDT. 
 
1.6 Subcellular targets of PDT 
Because of the limited migration of 1O2 from the site of its formation, sites of 
initial cell and tissue damage of PDT are closely related to the localization of the 
sensitizer (Peng et al. 1996). Although sensitizers can accumulate in different 
cellular compartment, the preferential sites are represented by the mitochondria 
and the endoplasmic reticulum (Table 1, Almeida et al. 2004).   
 
1.6.1 Mitochondrial damage 
It is now known that most photosensitizers localize in the mitochondria, and 
that, exerting their primary action there, rapidly induce apoptosis (Kessel 1998). 
The very early event after PDT treatment is the cytochrome c release from 
mitochondria (Ferri  et al. 2001). Several studies showed, in fact, that in HeLa and 
in leukaemia cells treated with benzoporphyrin derivative (BDP) and Pc4, 
respectively, and light, cytochrome c, released into the cytosol immediately after 
exposure to light, activated caspases (Granville et al. 1998; Varnes et al. 1999). 
Studies based on different cell models and various sensitizers targeting 
mitochondria have shown that the cytocrome C release may rely on the induction 
of permeabilization of mitochondrial membranes probably due to variations of 
intracellular Ca2+ .  
The released cytochrome C acts by forming a complex named apoptosome,  that 
ultimately is responsible of activation of caspase 3, the final step of the apoptotic 
process. Furthermore, it was demonstrated that several sensitizers can activate 
caspase 8, and in turn caspase 3, by means of multimerization of the FAS/TNF 
receptor induced by singlet oxygen (Moore 2000).   
Recently, numerous research groups has focused their studies on the  
function of Bcl-2 family in PDT in consideration of their relationship with 
mitochondria.  The  Bcl-2 family can be subdivided in two groups based on their 
role in apoptotic cell death: Bcl-2, Bcl-XL, Mcl-1 that have anti-apoptotic activity 
and Bax, Bak, Bid that are pro-apoptotic factors.  
Bcl-2 is a protein, which is found in the outer membrane of the mitochondria, as 
well as in the endoplasmic reticulum and the nuclear envelope. It is known that 
over-expression of Bcl-2 can cause resistance to chemo-therapeutic drugs and 
radiations. In contrast the role of Bcl-2 in PDT is ambiguous.  
It has been shown that the over-expression of Bcl-2 inhibited the DNA 
fragmentation and apoptosis in the Chinese hamster ovary cell lines (CHO) loaded 
with Pc4 and irradiated by the prevention of cleavage of pro-caspase 3 and 9 
(Granville et al. 1999). The regulatory role of Bcl-2 in PDT has also been 
confirmed by trasfecting antisense Bcl-2 sequence in a retroviral vector into a  
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human gastric adenocarcinoma cell line. In this case a remarkable decrease of cell 
viability was observed.  
It has also been reported that the event that protects the cells irradiated from 
apoptosis is a phosphorylation event of Bcl-2 at Ser 70, mediated by the action of 
CDK-1, during G2/M arrest (Vantieghem et al. 2002).  
Very interestingly, it has been reported that PDT causes in vivo and in vitro a 
down-regulation of Bcl-2 antiapoptotic activity. Such down-regulation has been 
possibly explained assuming that Bcl-2 undergoes a conformational change or 
even an oxidative damage by PDT produced ROS (Castelli et al. 2004 and Moore 
2000). In whole, these studies clearly indicate that PDT may induce specific post-
traslational modification in Bcl-2 which may be a direct target of the 
photogenerated ROS or a down stream effectors of signal transduction. 
 
1.6.2 Endoplasmic reticulum damage 
In eukaryotes, the role of endoplasmic reticulum (ER) is linked to two 
specific functions: a) Ca2+ storage and signalling and b) folding, remodeling and 
sorting of newly synthesized proteins. Disturbances in any of these functions can 
lead to ER stress. It is now known that the ER stress may determine changes in 
protein folding and subsequent activation of the unfolded protein response (UPR).  
The UPR is a primarily pro-survival response activated to reduce the 
accumulation and aggregation of unfolded or misfolded proteins and to restore 
normal ER functioning prevalently by the induction of molecular chaperones 
(Schroder  et al. 2005). However, if ER stress persists, the UPR can activate a cell 
death program, which generally converges into the caspase-activation cascade.  
The cellular stress in fact may trigger the activation of ER trans-membrane 
stress receptors: ER kinase (PERK), activating transcription factor 6 (ATF6) and 
inositol requiring enzyme 1 (IRE1). This event directs the translation of certain 
genes, such as that encoding for activating transcription factor 4 (ATF4) that may 
promote cell survival, through the induction of genes involved in restoring ER 
homeostasis, or favour apoptosis, through the induction of the transcription factor 
C/EBP homologous protein (CHOP). Importantly, the induction of CHOP leads to 
the down-regulation of expression of  Bcl-2, which favours cytochrome c efflux 
and mitochondrial apoptosis. On other hand, the activation of RE stress receptors 
(and in particular of IRE1) may determine the recruitment of TRAF-2 in a 
complex to activate caspase 12 or the activation of JNK (c-Jun N-terminal kinase) 
and p38-MAPK, key molecules in the modulation of apoptosis induction.  
Recent data indicate that following PDT, different heat shock proteins as 
well as the ER chaperones, GRP78/Bip, calreticulin, calnexin are induced in a 
time dependent manner (Mak et al. 2004).  
In addition, it has been also demonstrated that several photosensitizers may cause 
the induction of CHOP, activation of the ER stress-mediated caspase-12 and 
apoptosis (Grebenova et al. 2003).  
A recent genome-wide analysis in hypericin-PDT exposed bladder cancer cells 
(T24 cells) revealed that proximal molecular sensors and effectors of the UPR are 
induced in a coordinated manner (Buytaert E et al. 2007). 
 20 
These studies uncover that perturbations in the ER caused by accumulation of 
photo-oxidated/misfolded proteins can persistently activate the UPR pathway. 
Hence the functional impact of the UPR on the modulation and efficiency of 
PDT-induced cell death in cancers should be further evaluated both in vitro as 
well as in vivo. 
 
1.7 Ubiquitin- Proteasome pathway  
The ubiquitin-proteasome pathway (UPP) strictly controls the degradation of 
most cellular proteins (~80%) in eukaryotes. It consists of two systems that work 
together: the ubiquitin-conjugating system and the proteasome (Fig. 3, Glickman 
et al. 2002). UPP plays a critical role in degradation of key signalling molecules 
that promote cell cycle progression, cellular adhesion, proliferation and induction 
of anti-apoptotic pathways (Voges et  al. 1999). Accordingly, the proteasome is an 
attractive target for the cancer therapy. Recently, it has been shown that UPP 
system play a pivotal role in the degradation of many short lived functional 
proteins and in the breakdown of the proteins that come unfolded in response to 
oxidative damages. The reactive oxygen species, in fact, can promote the partial 
unfolding of the proteins, exposing hydrophobic domains to proteolytic enzymes 
constituting the proteasome core (Fribley et al. 2004).  
 
 
Fig 3: In the ubiquitin-proteosome degradation pathway, Ub is first covalently ligated to 
target proteins by a multi-enzymatic system consisting of Ubiquitin-activating (E1), Ubiquitin-
conjugating (E2), and the Ubiquitin-ligating (E3) enzymes. Ubiquitinated protein is then escorted 
to the 26S proteasome where it undergoes final degradation and the ubiquitin is released and 
recycled  
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1.8 Mechanism of UPP action  
The UPP is characterized by a cascades of controlled steps and  represents a 
system finely conserved in the evolution.  
The intracellular proteins are targeted for degradation by the conjugation of 
multiple molecules of ubiquitin (Ub). This process occurs through a multi-
enzymatic system consisting of a Ub-activating (E1), Ub-conjugating (E2), and 
Ub-ligating (E3) enzymes, which act in a sequential manner and allowing the 
protein recognition by the proteasome (Adams 2003). The proteasome is a large 
multi-subunit protease complex that rapidly catalyzes the degradation of the 
Ubiquitin-tagged proteins (Ubiquitin is recycled the in an ATP dependent fashion, 
Almond et al. 2002). The proteasome is localized in the nucleus and cytosol and 
consists of two multisubunit functional components: a single catalytic 20S core 
and two regulatory 19S flanking regions.  
The 20S core is comprised of four stacked rings (two outer -rings and two 
inner -rings), each comprising seven distinct but structurally related subunits 
termed 1-7 and 1-7, to form a cylindrical structure. The proteolytic activity is 
confined to the β−subunits (β1, β2 and β5), at the center of 20S core, and is 
characterized by 3 enzymatic activities: chymotrypsin-like, trypsin-like, and post-
glutamyl peptide hydrolase-like. After the progressive degradation of the tagged 
protein, the protein substrate is release as small peptides (from 3 to 22 amino 
acids).  
The regulatory 19S unit of the proteasome contains the polyubiquitin-binding 
sites and the isopeptidase activity necessary for the cleavage and release of 
Ubiquitin to the protein substrate. It also contains six different ATPases that 
unfold the protein substrate and facilitate its degradation.  
 
1.9 Pharmacological inhibitors of proteasome system 
It has been shown that  the deregulation of UPP system is involved in the cell 
malignant transformation. Several studies on patient-derived chronic lymphocytic 
leukaemia (CLL) cells, in fact, have demonstrated that they are characterized by 
3-fold higher levels of chymotrypsin-like proteasome activity than normal 
lymphocytes (Masdehors et al. 2000). It is now known that low levels of some, as 
p27 or p21, that are normally degradated by UPP system, are associated to worse 
prognosis (Zhan et al. 2002 and Spataro et al. 1997). On other hand, it has been 
shown that the fibroblasts transformed with ras and c-myc resulted up to 40-fold 
more susceptible to apoptosis than normal human lymphoblasts if treated with the 
peptidyl aldehyde MG-132, a proteasome inhibitor (Orlowski et al. 1998 and 
Guzman et al. 2002). It is been shown that the selective citotoxicity of proteasome 
inhibitors on cancer cells is probably due by the presence of intact checkpoints in 
the normal cells which allow the recover the damage. 
Recently numerous synthetic and biologic drugs, that inhibit the UPP 
activity, have been identified. These inhibitors act prevalently on the core particle 
by binding irreversibly or reversibly the active sites with different activities. They 
include the already cited synthetic peptide aldehydes MG-132, and Lactacystin, 
Epoxomicin and the class of peptide boronic acids (Adams 2003).   
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Many of these compounds, however, while having a poor metabolic stability bind 
too tightly to their substrate. To date, the most promising proteasome inhibitor is 
the class of peptide boronic acids. These compounds are extremely selective for 
the proteasome by blocking the chymotrypsin-like activity but in a reversible 
manner. Within this class of peptides, the dipeptidyl boronic acid  have the 
advantage of a relatively low molecular weight and simplicity of synthesis. The 
water-soluble dipeptidyl boronic acid Bortezomib is an extremely potent (Ki= 0,6 
nM), reversible and selective proteasome inhibitor. It binds the proteasome with 
very high affinity and dissociates slowly, conferring stable but reversible 
proteasome inhibition (Kisselev et al. 2001).  
Accordingly, Bortezomib (Velcade®) is the first proteasome inhibitor approved to 
the Food and Drug Administration for treatment of multiple myeloma.   
One the first indications of potential use of Bortezomib in cancer treatment, 
was the results obtained screening 60 cell lines derived from multiple human 
tumours at National Cancer Institute (Bethesda, MD, USA). This screening 
indicated that Bortezomib potently inhibited the growth at very low concentration 
(~ 7 nM) inducing G2-M cell cycle arrest and apoptosis (Ling et al. 2002 and 
Frankel et al. 2000). 
The precise mechanism by which proteasome inhibitors induce cell death are 
yet to be fully established. However, it has been demonstrated the stabilization of 
several important proteins, often dysregulated in many human malignancies, are 
controlled by the proteasome including the inhibitor of the tumour suppressor p53, 
the cyclin and cyclin-dependent kinase inhibitors p21 and p27 and the nuclear 
factor NFκB (IκB) (Almond et al. 2002).  
The control of NF- κB pathway by the inhibition of proteasome system is of 
particular interest in the cancer treatment. More recent evidence supports, in fact, 
the role of this nuclear transcription factor in tumorigenesis, in the suppression of 
apoptosis, in the enhancement of tumour cell invasiveness and metastasis, and in 
the induction of angiogenesis (Orlowski et al. 2002).  
Under normal circumstances, NF−κB is sequestered in the cytoplasm and 
rendered inactive by its association with the inhibitor protein IκB that blocks its 
nuclear translocation. Furthermore, when the cells are stimulated by stress, the 
critical serine residues on IκB may be phosphorylated and the protein becomes a 
target for ubiquitination and degradation by the proteasome system. This event 
causes the traslocation of NFκB to the nucleus and the subsequent transcription of 
genes encoding for stress response enzymes, cell adhesion molecule, pro-
inflammatory cytokine and anti-apoptotic proteins as Bcl-2. (Chen et al. 2000). 
The proteasome inhibition stabilizes, therefore, the complex IκB / NF−κB which 
renders NF−κB transcriptionally silent (Fig. 4). 
 23 
 
 
 
Fig. 4: NF-κB initiates pro-survival pathways. NF-κB is a pivotal regulatory protein, 
activating the transcription of a number of genes, including growth factors, angiogenesis factors, 
cell adhesion molecules, and anti-apoptotic factors. In quiescent cells, NF-κB is located in the 
cytoplasm and is bound to an inhibitor protein, IκB. When the cell is stimulated by stress, growth 
factors, radiation, etc., IκB is degraded by the proteasome and NF-κB becomes free to translocate 
to the nucleus, where it activates transcription. Proteasome inhibition stabilizes the IκB–NF-κB 
complex, which renders NF-κB transcriptionally silent (from Adams J 2003).  
 
 
 
Accordingly, the expression of the “super-repressor” IκB in which critical serines 
are mutated to alanines (and cannot therefore be phosphorylated) prevents its 
proteasome-mediated degradation. In addition NF−κB remains sequestered in the 
cytoplasm, thereby mimicking the impact of proteasome inhibitors on this 
pathway. In a murine xenograft model of head and neck squamous cell carcinoma, 
expression of an IκB super-repressor, or treatment with Bortezomib, led to 
inhibition of tumour growth and angiogenesis and to down-regulation the vascular 
endothelial growth factor and NF−κB dependent pro-angiogenic cytokines 
(Sunwoo et al. 2001) 
Recently it has been demonstrated that the combination of proteasome 
inhibitor with a chemotherapeutic agent may increase the overall anti-tumour 
efficacy. The use of Irinotecan or Gemcitabine combined with Bortezomib in 
pancreatic and colon cancer (LoVo) xenograft models, in fact, determined tumour 
regression, although neither Irinotecan, Gemcitabine nor Bortezomib had striking 
activity as single agent for these typically refractory cancers (Cusack et al. 2001).  
The reason for this additive activity is not clear. It is now known that the most of 
chemotherapeutic approaches as the treatment with antineoplastic drugs, i.e 
Irinotecan and Gemcitabine, or radiations may induce an up-regulation of NF−κB,  
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a transcriptional factor that initiates pro-survival pathways. In such regard, the use 
of Bortezomib, that alone causes a down-regulation of NF−κB, may provide an 
additional anti-tumour effect in cells that, constitutively or in response to 
traditional antineoplastic approaches, express high levels of this nuclear 
transcription factor.  
 
1.10 A new inhibitor of proteasome system: Aspirin 
Historically, the anti-inflammatory drugs had their origin in the unexpected 
discovery that several plants and their extracts may apply for the treatment of 
fever and inflammation. In the mid-19th century it has been developed the 
chemistry of salicylates and subsequently the acetyl-salicylic acid or aspirin.  
The clinical utility of non-steroidal anti-inflammatory drugs (NSAIDs) 
results from their ability to inhibit the activity of cyclooxygenase (COX). COX is 
important in the transformation of arachidonic acid into prostanoids, 
prostaglandins and thromboxane A2 (Vane 1971). NSAIDs include not only 
Aspirin, first-generation non-selective inhibitors of both COX-1 and COX-2, but 
newer second-generation drugs that inhibit primarily COX-2. The two functional 
isoforms of COX, termed COX-1 and COX-2, play important roles. In particular, 
the activity of  COX-2 is crucial in stress responses.  
Recently, It has been shown that COX-2 is hyper-expressed in colon as well as in 
other human cancers (neck, breast, lung tumours). Several, but not all, 
epidemiological studies have reported a reduction in colon cancer incidence 
associated with the use of aspirin. (Giovannucci et al. 1995).  
It is been recently demonstrated that low doses of Aspirin induces a 
proteasome dysfunction preventing the degradation of several substrates as p27, 
p21 and IκB. In particular the failed degradation of  IkB may block the nuclear 
translocation and transactivation of NF-kB and the transcription of pro-survival 
genes.  
Because the proteasome system is involved in the degradation of many short-lived 
proteins that are required for cell survival, it is clear that the dysfunction of this 
pathway may promote cell death. In fact, the block of proteasome system by 
Aspirin or other pharmacological inhibitors, promotes cell death by apoptosis in 
different human cell lines (Dikshit et al. 2006).  
Several studies have demonstrated that the inhibition of proteasome activity 
causes apoptosis by two mechanisms: caspases activation (Bellosillo  et al. 1998), 
and/or down-regulation of anti-apototic proteins, such as Bcl-2 (Zhang et al. 
2000).  
It has been demonstrated that Aspirin-mediated apoptosis in several cell lines may 
also depend on the arrest of cell cycle, probably because the large accumulation of 
proteins, such as p27 or p21 (Luciani et al. 2007). The inhibition of proteasome 
system, however, is related to the direct inhibition of the enzymatic activity or to 
the indirect inhibition of the various proteasome subunits. Further studies are 
however required to establish the molecular mechanism of proteasome inhibition 
by Aspirin in cancer.  
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2. AIM OF THE STUDY 
 
Photodynamic therapy (PDT) is a minimally invasive therapeutic modality 
approved for treatment of many diffused human diseases including cancer. In fact, 
PDT is finding increasing application for the treatment of different tumours. 
Several observations from our own as well as other groups, indicate that 
photodynamic therapy acts on tumours through direct ROS-mediated 
photodamage. This action involves oxidative effects on cellular components 
including proteins. It has been shown that UPP system plays a pivotal role in the 
breakdown of the proteins that come unfolded in response to oxidative stress. 
The aim of this work is to clarify the role of UPP system in response to ROS-
mediated photodamage in cells. Since it has been demonstrated, that Aspirin may 
cause a block of proteasome activity, we have investigated the possible 
implications for therapy deriving from a combined use of PDT with Aspirin. To 
this purpose two lung cancer cell lines (H1299 and A549), notoriously resistant to 
conventional antineoplastic treatments, were selected.  
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3. MATERIAL AND METHODS 
 
3.1 Cell Cultures  
The H1299 human non–small cell lung cancer cell line was obtained from 
American Type Culture Collection (Rockville, MD). They were cultured in RPMI 
1640, 2 mmol/L L-glutamine, 10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 
4,500 mg/L glucose, 1,500 mg/L sodium bicarbonate, 100 Ag/mL streptomycin, 
100 units/mL penicillin, and 10% FCS. The H1299 cells are p53-/- . 
The A549 human non–small cell lung cancer cell line was obtained from 
American Type Culture Collection (Rockville, MD). They were cultured in Ham’s 
F12K, 2 mmol/L L-glutamine, 1,500 mg/L sodium bicarbonate, 100 units/mL 
penicillin and 10% FCS. All media and cell culture reagents were purchased from 
Life Technologies (San Giuliano Milanese, Italy). The A549 cells are p53 +/+.  
 
3.2 Materials  
The Photofrin (the Hematoporphyrin derivative Porfimer sodium) used in 
this work was supplied as freeze-dried powder (lot no. 162A6-06; Axcan Pharma, 
Mont-Saint- Hilaire, Quebec, Canada). Its absorption spectrum consists of various 
peaks within the visible region. A Photofrin stock solution was prepared by 
dissolving the powder in water containing 5% glucose to obtain a final 
concentration of 2.5 mg/mL. This solution was stored in aliquots at -20°C in the 
dark. Before measurements, appropriate aliquots of this solution were diluted to 
the desired concentration.  
Cells were routinely irradiated by a broadband light delivered with  a PTL-
Penta apparatus (Teclas, Sorengo, Switzerland) consisting of a halogen lamp 
(Osram 250 W, 24 V  Osram, Munich, Germany) equipped with a bandpass filter  
(>80% transmittance in the 510 to 590 nm spectral region). The light was 
delivered  through an 8-mm bundle of optical fibers placed at a  distance from the 
cell plates that ensures uniform illumination of the entire cell monolayer. The 
fluence rate at the level of the cell monolayer was fixed at 6 mW/cm2 and the light 
dose used was fixed at 0.54 J/cm2. 
Acetylsalicylic acid (Aspirin or ASA) used in this work was supplied as 
powder by Sigma Aldrich (St Louis USA). An Aspirin stock solution was 
obtained by its dissolution in TRIS 1 M pH 8,8 to a final concentration of 110 
mmol/l. Before the use, appropriate aliquots of this solution were diluted to the 
desired concentration.  
Cycloheximide used in this work was supplied as powder by Sigma Aldrich 
(St Louis USA). The Cycloheximide is an inhibitor of protein biosynthesis that 
blocks the translation of messenger RNA on cytosolic, 80 S ribosomes, but does 
not inhibit organelle proteine synthesis. The Cycloheximide stock was obtained 
by its dissolution in water to a final concentration of  100 mg/ml.  
The proteasome inhibitor MG-132 was obtained from Calbiochem, La Jolla, 
CA. MG-132 is a peptide aldehyde that inhibits ubiquitin-mediated proteolysis by 
binding to and inactivating 20S and 26S proteasomes (Rock et al. 1994). 
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 A stock solution of 150 µg/ml of this reagent (Z-leu-leu-CHO) was prepared in 
normal medium containing 7.5 µL per ml dimethylsulfoxide (DMSO).  
The Dithiothreitol (DTT), efficient radical oxygen scavenger, was obtained 
from Sigma Aldrich (St Louis USA). A stock solution was prepared in water and 
conserved to -20 °C. Before use appropriate aliquotes were diluted.  
 
3.3 Drug treatments 
In individual experiments 400000 cells were incubated at 37°C in the dark 
with 2.5 µg/mL of Photofrin for 16 hours before irradiation or with Aspirin for 24 
hours or 48 hours. In combined treatment the cells were incubated respectively 
with Aspirin (0-24 hours) and Photofrin (8-24 hours) or with Photofrin (8-24 
hours) and, after irradiation, with Aspirin for 24 hours.  
The effect of mono-therapy with PDT or with Aspirin or combined therapy 
were evaluated at the times indicated elsewhere by: a) by Trypan Blue and MTS 
assay, to check the cell viability, b) by Colony Forming Assay, to test the capacity 
to form colonies, c) by cytofluorimetry, to determine the cell distribution and ROS 
amount, d) by Western Blot, to analyze protein expression patterns. 
 
3.4 MTS assay  
Cell viability was assayed using CellTiter 96 Aqueous One Solution  Non–
Radioactive Cell Proliferation Assay (Promega, USA). According to the supplier, 
5x 104 cells were seeded into 96-well plates, incubated with Aspirin (0, 5.0, 10.0 
mm/L) for 24 or 48 hours. The cells subjected to PDT treatment were treated with 
Photofrin for 16 hours and then irradiated. Each culture condition was analyzed in 
triplicate. The absorbance values at 492 nm were corrected by subtracting the 
average absorbance from the control wells containing ‘‘no cells”.  
 
3.5 Colony-forming efficiency 
Colony forming efficiency assay was assayed in triplicate by seeding in 6 – 
well plates, 2 x104 cells which have survived to the various treatments: a) Aspirin 
0 and 10 mmol/L b) PDT 0.54 J/cm2  c) Aspirin followed by PDT d) PDT 
followed Aspirin. After 8 to 10 days, colonies (> 50 cells) were stained with 1% 
methylene blue in 50% ethanol.  
 
3.6 Flow Cytometry   
Dishes (10 cm) containing 4 x 105 H1299/ A549 cells were  incubated for 24 
hours at 37 ° C in 7 mL complete medium (controls) or in medium supplemented 
with Photofrin (2.5 µg/mL) alone or associated with Aspirin (5 e 10 mm/L) for 24 
hours. Cells were exposed to single and/or combined treatments as described 
above and were then detached from the dishes by trypsinization, suspended in 
serum rich medium, centrifuged, washed twice with 1 mL PBS, and resuspended 
for storage (20°C) in 95% ethanol.  Before analysis, fixed cells were washed 
twice, centrifuged, and resuspended in 1 mL PBS containing 1 µg  RNase and 100 
µg propidium iodide (Crescenzi et al. 2004). Samples were stored in the dark for 
20 minutes at room temperature before final readings.  
 28 
The cellular orange fluorescence of Propidium Iodide was detected in a linear 
scale using a flow cytometer (FACScan, Becton Dickinson, Mountain  View, CA) 
equipped with an excitation laser line at 488  nm. About 30,000 events (i.e., 
fluorescence readings, corresponding to not less than 20,000 cells) were recorded  
for each sample. The cell cycle was examined after monotherapy and combined 
treatment at the indicated times. Data were analyzed with ModFit/LT (Verity 
Software, Topsham, ME).  
 
3.7 Measurement of ROS production 
Reactive oxygen species were detected with H2DCFDA (Calbiochem). 
H2DCFDA diffuses into the cells where it is converted into a non-fluorescent 
derivative (H2DCF) by endogenous esterases. H2DCFDA is oxidized to green 
fluorescent DCF in the presence of intracellular ROS (Caro et al. 1996). Cells 
before PDT were washed and incubated at 37 °C in serum-free medium alone or 
in the presence of DTT 1 mM. After 30’ the cells were incubated in the presence 
of H2DCFDA in serum-free medium. After 30’ the cells were washed with 
Hank’s, irradiated, detached by trypsinization and resuspended in phosphate-
buffered saline, then analyzed immediately by flow cytometry using a FACScan 
Cell Scanner (BD Biosciences). 
 
3.8 Western Blot Analysis  
Total cell protein preparations were obtained by lysing cells in 50 mmol/L 
Tris (pH 7.5), 100 mmol/L NaCl, 1% NP40, 0.1% Triton, 2 mmol/L EDTA, 10 
Ag/mL aprotinin, and 100 Ag/mL phenylmethylsulfonyl fluoride. Protein 
concentration was routinely measured with the Bio-Rad protein assay (Bradford 
1976). Polyacrylamide gels (10–15%) were prepared essentially as described by 
Laemmli (Laemmli 1971). Molecular weight standards were from New England 
Biolabs (Beverly, MA). 
Proteins separated on the polyacrylamide gels were blotted onto nitrocellulose 
filters (Hybond-C pure, Amersham Italia, Milan, Italy). Filters were washed and 
stained with specific primary antibodies and then with secondary antisera 
conjugated with horseradish peroxidase (Bio-Rad; diluted 1:2,000). Filters were 
developed using an electro-chemiluminescent Western blotting detection reagent 
(Amersham Italia) and quantified by scanning with a Discover Pharmacia scanner 
equipped with a Sun Spark Classic Workstation. The anti-Bcl-2 (100), p27 (C-
19); Ikb (C-15) and actin (C-2) antibodies were from Santa Cruz Biotechnology 
(Santa Cruz,  CA). Anti-tubulin  (MCA77G) was from Serotec. 
 
3.9 Cycloheximide experiments 
H1299 cells were plated onto 100 mm cell culture dishes and an the 
following day, cells were incubated with Photofrin for 16 hours then washed 
twice and incubated with 40 µg of Cycloheximide. After three hours the cells 
were washed, irradiated and replaced in a fresh complete medium. Cells collected 
at each time point (1, 2, 3 and 6 hours) were then processed for immunoblotting 
using antibodies against IκB. Anti-Tubulin antibody has been used to normalize.    
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3.10 Immunoprecipitation 
Dishes (10 cm) containing 4 x 105 H1299 cells were incubated for 24 hours 
at 37° C in 7 mL complete medium (controls) or in medium supplemented with 
Photofrin (2.5 µg/mL) for 16 hours or in medium containing 10 µM of MG-132 
for 3 hours. Cells were exposed to photodynamic therapy (0.54 J/cm2) as 
described above. Total cell protein preparations were obtained by lysing cells in 
RIPA buffer (1% Nonidet P40, 0.1% SDS, 0.5% sodium deoxycholate), 10 
Ag/mL aprotinin, 100 Ag/mL phenylmethylsulfonyl fluoride, and phosphatase 
inhibitors (Sigma). Protein concentration was routinely measured with the Bio-
Rad protein assay (Bradford 1976).To cell lysate sample was added 20 µl of anti- 
IκB (N-19) antibody, incubated overnight at 4°C, and gently mixed on a suitable 
shaker. The sample was treated with 40 µl of γ binding Sepharose, incubated 
overnight at 4°C, washed twice with RIPA buffer. Proteins separated on the 
polyacrylamide gels were blotted onto nitrocellulose filters (Hybond-C pure, 
Amersham Italia, Milan, Italy). Filters were washed and stained with anti-Ub (C-
15) antibody and then with secondary antisera conjugated with horseradish 
peroxidase (Bio-Rad; diluted 1:2,000). Filters were developed using an electro-
chemiluminescent Western blotting detection reagent (Amersham, Italia) and 
quantified by scanning with a Discover Pharmacia scanner equipped with a Sun 
Spark Classic Workstation. 
 
3.11 Statistical analysis  
All the data were expressed as mean ± SD. Significance was assessed by Student's 
t test for comparison between two means. P values of less than 0.05 were 
considered statistically significant. 
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4. RESULTS AND DISCUSSION 
 
4.1 PDT induces ROS- mediated cell death  
Several studies in vitro have demonstrated that PDT induce cell death in 
many cell lines. Investigations from our own as well as other groups evidenced 
that PDT may cause apoptosis or necrosis depending on many factors including 
the intracellular localization of photosensitizer and the light fluence (Oleinick et 
al. 2002 and Dennis et al. 2003). In this work we used two human cell lines, 
namely H1299 and A549, both derived from human non-small cell lung cancer 
(NSCLC) cells that  differ for the key protein p53 which is null (-/-) in the former 
and wild-type (+/+) in the latter strain. Moreover, the A549 human lung 
adenocarcinoma cells are particularly resistant to conventional antineoplastic 
therapy (i.e. chemotherapy, radiation) while presenting high basal levels of NF- 
κB.  
To have some insight on the molecular mechanism determining the increased 
susceptibility to PDT stress-induced cell death, we checked the radicals oxygen 
species (ROS) production at different light doses in the H1299 and A549 cell 
lines. As shown in Figure 5 when the light fluence increase from 0 to ~ 1.40 
J/cm2, the ROS production is enhanced proportionally in both cell lines.  
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Figure 5: PDT induces ROS accumulation. H1299 and A549 cell lines were incubated 
with Photofrin (16 hours) then washed and incubated with 5 µM of H2DCFDA in free serum  
medium. After 30’ the cells were irradiated with different light doses (a, b, c, d, e from 0 to 1.40 
J/cm2). The reactive oxygen species (ROS) were determined by cytofluorimetry.  
 
 
The preliminary experiments consisted in assaying the effective role of reactive 
oxygen species (ROS). This has been done by comparing  the viability, by MTS 
assay, of cells irradiated directly or pre- treated with 1 mM Dithiothreitol (DTT). 
As shown in Figure 6, DTT protects A549 (upper panel) and H1299 (lower panel)  
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cells from death. These data suggest that the cell death in both cell lines was due 
to an accumulation of ROS. 
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Figure 6: PDT induces ROS- mediated cell death. H1299 (upper panel) and A549 (lower 
panel) were irradiated and/or pre- treated with 1 mM Dithiothreitol (DTT). The cell viability was 
assessed by MTS assay 24 hours after treatment. Data are mean ± S.D. from three experiments. 
 
 
4.2 Sub-lethal photodynamic treatment reversibly inhibits the 
proteasome function  
The cytotoxic effects of PDT are mediated by the production of reactive 
oxygen species (ROS). Due to the high reactivity and unspecific choice of 
substrate, such species exert their harmful effects on the cell at the site where they 
are generated: in the nucleus they damage DNA, in the membranes fatty acids and 
in the cytoplasm target proteins. At low concentrations as 2.5 µg/mL and less than 
24 hs of incubation, Photofrin is mostly concentrated in the cytoplasm (Hsieh YJ 
et al. 2003). In these conditions the major photodynamic effects concerns the 
cytosolic proteins. 
 Several in vitro studies have shown that the UPP system plays a major role in the 
breakdown of abnormal proteins that result from  an oxidative stress. In fact, it is 
known that oxidation may damage and even irreversibly denature proteins. The 
resulting unfolded molecules are rapidly tagged with ubiquitin and successively 
degraded by the proteasome machinery (Fribley et al. 2004).  
To explore the mechanism of stress response induced by a sub-lethal 
photodynamic treatment in the H1299 and A549 cell lines we analyzed the  
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expression profile of proteins, like as p27, IκB factor and Bcl-2. Such proteins are 
routinely processed by proteosomal degradation. In our experience, within two 
hours following the irradiation the expression levels of the proteins p27, IκB and 
Bcl-2 significantly increases (Fig.7). Such raise amounts to ~1.3-1.4 folds over the 
control.  After two hours, however, the proteins expression levels tend to fade and 
return to the original (or lesser) value.  
 
 
Control 1 h 2 h 3 h
PDT 
(0.54 J/cm-2 )
Actin
Bcl-2
p27
Control 1 h 2 h 3 h
PDT 
(0.54 J/cm-2 )
IκB
 
Figure 7: Sub-lethal photodynamic treatment reversibly inhibits the proteasome 
function. H1299 (right panel) and A549 (left panel) were incubated with Photofrin for 16 hours 
then irradiated (0,54 J/cm2). The extraction of total proteins was performed 1, 2, 3 hours after 
PDT. The expression of Bcl-2, IκB and p27 was evaluated by Western Blot. Both panels show an 
increase of expression extended up two hours followed by fading or disappearance at longer time ≥ 
3 hours. Anti- Actin antibody has been  used to normalize.  
 
 
While no earlier observations have been reported to now concerning p27 and 
IκB behaviour upon photodynamic treatment with Photofrin, the increase in the 
expression of Bcl-2 within the first two hours appears in contrast with previous 
observations (Ferrario et al. 2005). Other authors describe a direct Bcl-2 damage 
by photodynamic treatment with various photosensitizers (Xue et al. 2001 and 
Usuda et al. 2003), different photosensitizer concentrations and/or other 
experimental conditions (Ferrario et al. 2005).  
Our findings suggest that Photofrin-PDT, at a dose of 0.54 J/cm2, induces a 
transient stall of proteasome activity (< 3hs) in H1299 and A549 cell lines.  
Within this window of light fluences, the H1299 and A549 viability remains 
at appreciable levels and does not noticeably change within 6 hours (decrease of ~ 
30% respect to the control). It is noteworthy that in both cases at three hours post 
irradiation the proteasome appears to reactivate its function. The same result is 
obtained at higher (1.25 J/cm2) (Fig. 8) while at lower energy (0.18 J/cm2) the 
proteasome block is not even observed (not shown). The behaviour of A549 cells 
is fully super imposable to that of H1299 cells. 
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Fig. 8: High energy causes a transient block of proteasome activity. H1299 was 
incubated with Photofrin for 16 hours then irradiated at high energy (1,25 J/cm2). The extraction of 
total proteins was performed 1, 2, 3, hours after the photodynamic treatment. The expression of 
Bcl-2 and p27 was evaluated by Western Blot. An increase of both proteins was shown at short 
time compared with the control. Anti-Actin antibody has been used to normalize.     
 
4.3 PDT in presence of radicals oxygen scavengers is not able to inhibit 
proteasome activity 
It has been demonstrated that the severity of cell damage, caused by different 
stimuli as radiation or chemotherapy, depends on the amount of ROS generated 
within the cell. A large production of ROS induces, in fact, the death of cancer 
cells by apoptosis or necrosis while small ROS production can activate other 
cellular pathways. To verify whether the increased production of ROS was 
responsible of the transient stall of proteasome activity, the cells subjected to 
Photofrin-PDT were pre-incubated with 1 mM Dithiotreithol (DTT) (fig. 9).  
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Figure 9: Dithiotreithol (DTT) effect on proteasome activity. H1299 cell line was pre-
treated with DTT (1 mM) then irradiated. The extraction of total proteins was performed 1, 2, 3, 6 
hours after the PDT. The expression of Bcl-2 and p27 was evaluated by Western Blot. The right 
panel shows that DTT abolished the proteasome stall. Left panel show confirmed that, at the same 
conditions, the cells pre-incubated with DTT are characterized by a decrease of ROS amount.  
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DTT is an efficient scavenger of oxygen radicals. The expression levels of target 
proteins was evaluated by western blot; the ROS levels were determined by flow 
cytometry. It is interesting that in these conditions the transient accumulation of 
Bcl-2, p27 and IκB proteins was no longer observed (as shown in Fig. 9). These 
results demonstrate that an effective inhibition of ROS formation prevented 
proteasome stall. Similar results were obtained by using another reducing agent as 
N-acetylcysteine (NAC), at a dose of 1 mM (not shown). 
 
4.4 Photodynamic treatment increases the ubiquitination level of  
proteins 
To investigate the mechanism of the proteasome malfunction, we evaluated 
the ubiquitination profile of the cells after photodynamic treatment. It has been 
shown, in fact, that the inhibition of proteasome function leads to an increased 
levels of ubiquitinated proteins. In general, when the cell is extensively damaged 
and/or when the injury concerns the external membrane, it rapidly proceeds to 
necrosis. When the damage is not such as to kill immediately, cells may recover in 
full, may decide to proceed toward apoptosis or activate an autophagic program. 
Depending on the intensity and location of an oxidative stress all these fates may 
be evoked. In any case, however, a number of cellular proteins will result 
irreversibly denatured as result of the oxidative stress.  
The intracellular protein denaturation asks for the activation of cellular defence 
systems including ubiquitination of all those proteins that can not be rescued.   
Our findings suggest that Photofrin-PDT at the dose of 0,54 J/cm2 affects the 
ubiquitination profile of proteins extracted from irradiated cells as shown in 
Figure 10.  
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Figure 10: Photodynamic treatment increases the accumulation of ubiquitinated 
proteins. H1299 was incubated with Photofrin for 16 hour with 10 µM of MG-132 for 3 hours. 
After PDT (0.54 J/cm2) the proteins extracted were immunoprecipitated with anti-IκB and 
ubiquitin-conjugated IκB was detected by Western blotting. Anti-Tubulin antibody has been used 
to normalize. 
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We observed that the accumulations of the ubiquitinated proteins is induced 
within two hours after the photodynamic treatment. It is noteworthy that, in these 
conditions, the ubiquitination profile is similar to that obtained by treating the 
cells with a known and specific pharmacological proteasome inhibitor, namely 
MG-132.  
According with previous observation, three hours post incubation the 
ubiquitination profile is changed back to that of non- irradiated cells (control). It is 
also interesting that, following PDT at the indicated conditions, the protein 
ubiquitination machinery is preserved while the non-lysosomal proteasome-
mediated protein digestion is ineffective. 
The observation that after PDT the levels of ubiquitinated protein were increased 
has been required further investigations.   
To this aim, the cells were incubated for three hours with 40 µg of 
Cycloheximide (CHX), a molecule that inhibits de novo protein biosynthesis 
before irradiation. After three hours the cells were washed, irradiated and replaced 
in a free-drug medium. Cells collected at each time point (1, 2, 3 and 6 hours) 
were then processed for immunoblotting using antibodies against IκB. As shown 
in Figure 11, the PDT treatment caused an increase in the accumulation of IκB, 
whose cytoplasmatic concentration is regulated by proteasome system.  
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Figure 11: Photodynamic therapy increases the stability of IκB. H1299 cells was 
incubated for three hours with 40 µg of Cycloheximide (CHX) before irradiation. After three hours 
the cells were washed, irradiated and replaced in a free-drug medium. Cells collected at each time 
point (1, 2, 3 and 6 hours) were then processed for immunoblotting using antibodies against IκB. 
Anti-Tubulin antibody was used to normalize.   
 
 
 
Such increase is due to the concomitant block of non-lysosomal protein 
degradation and the progressive (but not instantaneous) slowing down protein 
synthesis rate. As expected, three hours from exposure to light, IκB expression 
patterns changes back returning to the original profile. Accordingly, the up-
regulation of the proteins studied does not depend on de novo synthesis.  
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4.5 Proteasomal inhibition induces G2-M cell cycle arrest in 
photodamaged cells 
The increased accumulation of some proteins whose destiny is regulated by  
proteasome system might result in the cell cycle arrest and apoptosis.  
While no observations have been reported to now concerning cell cycle arrest 
mediated by proteasome inhibition after PDT, several studies have highlighted the 
relationship between the modifications of cell cycle profile and the treatment with 
pharmacological proteasome inhibitors. 
To evaluate the effect of PDT on cell cycle distribution, both H1299 and 
A549 were irradiated and analyzed by flow cytometry 6 hours after the treatment. 
Our findings suggest (Fig. 12, panels b-e) that PDT affects the cell cycle profile in 
both cell lines. The photodynamic treatment promotes the accumulation of H1299 
and A549 in the G2 phase of the cell cycle.  
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Figure 12: H1299 and A549 were incubated with Photofrin for 16 hours then irradiated.  
The cell cycle distribution was determined after 6 hours (panels b-e) and within 24 hours (panels 
c-f) after treatment, by cytofluorimetry. The cell cycle profile of controls were indicated in the 
panel a (H1299) and d (A549). Numbers, percentage of cells in G1, S, G2 phase.  
 
 
 
To further investigate the effect of cell cycle arrest in H1299 and A549 cell lines, 
the cell cycle distribution within 24 hours after PDT has been evaluated. As 
shown in Figure 12 (panels c-f), the accumulation of the cells in G2 was reduced 
and was accompanied by a re-establishment of the original profile (control) within 
24 hours. In such regard, we evaluated the capacity of these cells to re-start 
proliferation. To this purpose, H1299 and A549 cell lines were irradiated, 
extensively washed and incubated in a fresh complete medium. After 8 days, the 
capacity of these cells to refurbish the normal proliferation and form colonies was  
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investigated. As shown in Figure 13, consistent with the re-establishment of 
normal cell cycle distribution, both cell lines recovery quite in full their ability to 
form colonies.  
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Figure 13: Effect of PDT on clonogenic survival. Triplicate samples of H1299 and A549 cells 
were incubated with Photofrin for 16 hours then irradiated. After 8 days, colonies were stained 
with methylene blue. Data are mean ±S.D. from three independent experiments. 
 
 
 
Even the protein expression profile returns to the original patterns, as we 
already shown in a previous work (Crescenzi et al. 2006). 
In conclusion, these data showed that the PDT treatment in both cell lines 
causes within 6 hours a significant  accumulation of the cells in G2 cell cycle 
phase. Furthermore, the altering of the expression profile and cell cycle were 
reverted within 24 hours after photodynamic treatment. 
 
4.6 A second PDT treatment does not stabilize the proteasome stall.  
We have shown that following PDT the proteasome activity is arrested for 
about two hours. We decided to study the effects of a second irradiation (at the 
same light dose) exactly at two hours after the first exposure to the light. The 
expression profiles of key proteins was evaluated by western blot 1, 2, 3 hours 
after to the second treatment. As shown in Figure 14, although the second 
treatment prolonged the proteasome inhibition, this block appeared reversible. 
Furthermore, the stall of proteasome activity was reversible and the cells restored 
their capacity to proliferate. These data show that a second treatment is not able to 
sustain the block of the proteasome system. Also in such case the cells recover  
their capacity to proliferate. 
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Figure 14:Effect of a second PDT treatment on proteasome activity. H1299 cell line was 
irradiated, washed and incubated for two hours. In this interval the proteasome system was fully 
blocked. After two hours the cells were subjected to a second photodynamic treatment at the same 
dose (0,54 J/cm2). The proteins expression profiles was evaluated by Western Blot 1, 2, 3 hours 
after to the second treatment. The cell viability was determined by MTS Assay 24, 48, and 72 
hours after the second treatment.  
 
4.7 Aspirin reduces H1299 and A549 cells viability  
To investigate the effect on proliferation of Aspirin, the H1299 and A549 
carcinoma lung cancer cells were treated with Aspirin for 24 or 48 hours at two 
different concentrations (5 and 10 mM) as shown in Fig. 15.  
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Figure 15: Aspirin (ASA) reduces NCI-H1299 and A549 cell viability. A549 (upper 
panel) and H1299 (lower panel) were treated with 5 and 10 mM of Aspirin (ASA) and incubated 
for 24 or 48 hours. The cell viability were assessed by MTS assay 24 hours after the treatment. 
Data are mean ±S.D. from three independent experiments 
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It appears that Aspirin treatment induced a concentration-dependent 
reduction in the viability of both cell lines as judged by MTS assay (fig. 15).  
However, even after 48 hours of treatment with 10 mM Aspirin, the number 
of viable cells remained still elevated (~ 40% ) and did not really change also at 
concentrations above 10 mM (not shown). It appears that 10 mM Aspirin inhibits 
transiently cell proliferation but it is not fully toxic to cells.    
 
4.8 Aspirin at high concentration may induce G2 accumulation  
The arrest in cell proliferation observed upon Aspirin treatment of both cell 
lines requires the activation of specific cell cycle checkpoints. Previous 
observations on HCT116 have reported that low concentrations of Aspirin (≤5 
mM) may induce a cell cycle arrest in G1 phase (Goel et al. 2003). However, 
Subbegowda et al. 1998 showed that the human colon cell lines, treated with high 
doses of Aspirin (> 5 mM), were able to bypass G1/S checkpoint and favour G2/M 
arrest. To unravel the relationship between Aspirin and cell responses, we 
analyzed the cell cycle profiles of H1299 and A549 treated for 6 or 24 hours with 
10 mM Aspirin.  
We report that, after 6 h incubation, both H1299 and A549 accumulated in S, 
while at longer incubation (24 hours) we observed a significant ammassing of 
cells in the G2 phase (amounting to ~ 37 % in H1299 and ~ 27 % in A549, 
respectively, Fig. 16). 
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Figure 16: Effects of Aspirin (ASA) on cell cycle profile. H1299 and A549 were incubated 
with 10 mM of Aspirin for 6 (panels b-e) or 24 (panels c-f)  hours. The cell cycle distribution was 
determined by cytofluorimetry. Numbers, percentage of cells in G1, S, G2 phase.  
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In the latter conditions the number of cells populating the sub-G1 phase was rather 
small suggesting that the G2 arrest was not accompanied by apoptosis.  
Concomitantly, H1299 and A549 cell lines were assayed for viability by means 
of a clonogenic survival assay to detect the capacity of cells to recover the normal 
proliferation rate and form colonies. These data showed that both cell lines 
restored their full ability to form colonies (Fig. 17).  
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Figure 17: Effect of Aspirin (ASA) on clonogenic survival. Triplicate samples of H1299 
and A549 cells were incubated with 10mM Aspirin (ASA) for 24 hours and replated in drug-free 
medium. After 8 days, colonies were stained with methylene blue. Columns, mean of three 
independent experiments. Statistical analysis was by unpaired Student’s t test: **, p <0.002; ***, 
p<0.0001. 
 
In conclusion, these data suggest that high concentrations of Aspirin induce 
two divergent effects in H1299 and A549 cells. At 6 hours cells from both lines, 
appear to accumulate in the S phase, while at longer times a significant G2-M 
arrest is observed without apparent increase in apoptosis. Release of these cells in 
Aspirin-free medium rapidly restores their capacity to proliferate and to form 
colonies.  
 
4.9 Even Aspirin may determine a reversible arrest of proteasome 
activity.  
Recently, Diskshit et al. 2006 have demonstrated that the Aspirin treatment 
causes proteasome inhibition and apoptosis in Neuro 2a and HeLa cells. To 
evaluate the ability of Aspirin to affect the proteasome system in H1299 and A549 
cells, these were treated for 1, 2, 3 and 6 hours with 10 mM Aspirin, washed and 
then lysed to extract the proteins. The expression profile of proteins that normally 
undergo proteosomal degradation like as p27, IκB was obtained by Western Blot 
analysis. A significant accumulation of these target proteins was rapidly observed 
within the first two hours of treatment with 10 mM Aspirin (Fig. 18 right panel). 
At longer times, however the same proteins were progressively disappearing. Now 
we demonstrate that Aspirin increases the ubiquitination level of IκB (Fig. 18 left 
panel). Even such stall, however, is not sustained for long since the cells re-start 
to proliferate if released in drug-free medium as discussed before (Fig. 17 ).  
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Figure 18: Aspirin (ASA) may determine a reversible arrest of proteasome activity. 
H1299 cells was treated with ASA 10 mM for 1, 2, 3, 6 hours then lysed to extract the proteins. 
The expression profile of p27 and IκB was obtained by Western Blot analysis. The antibody anti-
tubulin was used to normalized. An increase of both proteins was shown within two hours 
compared with the control (right panel). The proteins extracted were immunoprecipitated with 
anti-IκB and ubiquitin-conjugated IκB was detected by Western blotting. An increase of 
ubiquitynation level of IκB was observed (left panel). 
 
 
 
4.10 Aspirin sustains the PDT-dependent G2 accumulation. 
As already observed, the treatment with Aspirin or PDT of H1299 and A549 
cell lines cell lines caused in both cases an accumulation of cells in G2. We have 
now investigated the effects of the combined treatment (PDT + Aspirin). To this 
purpose both cell lines were incubated with Photofrin for 16 hours then washed 
and irradiated (0.54 J/cm2). Immediately after photodynamic treatment these cells 
were incubated with 10 mM of Aspirin for 24 hours and then analyzed by flow 
cytometry. As shown in Figure 19 (upper panel), the combined treatment (PDT 
followed by aspirin) sustains G2/M accumulation with concomitant depletion of 
G1 phase in both cell lines.  
When we have inverted the order of treatment (Aspirin followed by PDT) a 
different result was obtained. In this case, H1299 and A549 cell lines were 
incubated with Aspirin (for 24 hours) and Photofrin (16 hours) then washed and 
immediately irradiated at the same light dose as before. Cells were replaced in 
fresh medium and analyzed 24 hours later by flow cytometry. As shown in Figure 
19 (lower panel), the accumulation of the cells in G2 observed upon individual 
treatments (Aspirin or PDT) was significantly reduced, the entire profile 
resembling that of the controls.  
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Figure 19: Aspirin sustains the PDT-G2  arrest.  H1299 and A549 were irradiated (0.54 
J/cm2). Immediately after photodynamic treatment were incubated with 10 mM of Aspirin for 24 
hours and then analyzed by flow cytometry (upper panel). H1299 and A549 cell lines were 
incubated with Aspirin (for 24 hours) and Photofrin (16 hours) then irradiated at the same light 
dose. Cells were replaced in fresh medium and analyzed 24 hours later by flow cytometry (lower 
panel). 
 
 
 
When the clonogenic assay was performed on cells under the two different 
regimens, we obtained results in agreement with cytofluorimetric data. In fact, as 
shown in Figure 20, cells that received Aspirin following PDT were not able to 
restore their clonogenic potential. Such behaviour may find explanation in the 
findings of Podhaisky et al. 1997 who demonstrated how Aspirin is able to 
regulate the proteins deputed to the protection against oxidative stress modulating 
ferritin expression. The ferritin is an iron-binding protein that, in addition to other 
functions, plays also an important role during oxidative stress by preventing iron-
mediated formation of oxygen radicals. Another possibility is that Aspirin may 
directly scavenge the oxygen radicals (Bellosillo et al.1998). 
In such conditions PDT becomes ineffective and Aspirin is destroyed. As 
shown in Figure 20, both cell lines pre-treated with Aspirin  are characterized by a 
normal capacity of establishing new colonies. In this case the effect of Aspirin is 
clearly additive in respect to that caused by PDT. The whole set of data suggests 
that the modality of treatment is important and is by no mean equivalent.   
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Figure 20: Effect of combined treatments on clonogenic survival. Cells were incubated 
for 24 hours with 10 mM of Aspirin then irradiated or subjected to PDT then incubated with 10 
mM of Aspirin for 24 hours. The cells were replated in drug-free medium. After 8 days, colonies 
were stained with methylene blue. Columns, mean of three independent experiments. Statistical 
analysis was by unpaired Student’s t test: **, p <0.002; ***, p<0.0001. 
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5. CONCLUSIONS 
Photodynamic therapy (PDT) is a minimally invasive therapeutic modality 
approved for treatment of many diffused human diseases, including macular 
degeneration, several dermatological disorders and cancer. Nowadays, PDT 
represents a very attractive modality of cancer treatment specially in combination 
with other conventional therapies as radio, immuno or chemo-therapy.  
In the present study we show that PDT leads to a reversible decrease in 
proteasome activity and a significant modification of cell cycle profile in two 
human non–small cell lung cancer cell lines. In both cases, the alteration of cell 
cycle profiles was reverted within 24 hours. In addition, cells recovered 
completely the clonogenic survival.  
Since it has been demonstrated, that Aspirin may cause a block of 
proteasome activity with a mechanism that still awaits full clarification, we have 
investigated the possible implications for therapy deriving from a combined use of 
PDT with this non toxic drug. Our data suggest that Aspirin may sustain the PDT 
G2-accumulation and concomitantly causes a decrease of clonogenic survival. 
Furthermore, a positive therapeutic effect is observed only when Aspirin 
administration follows the photodynamic treatment. 
In conclusion, appropriate doses of photosensitizer and light combined with low 
doses of a non toxic drug represent a promising strategy of treatment in cancer.  
In principle, combinations of PDT with non-toxic drugs, as Aspirin, would not 
only destroy cancer cells more efficiently but, being essentially side-effects-free, 
would also result more acceptable to patients.  
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Abstract We investigated the effect of modeled microgravity
(MMG) on normal vascular smooth muscle cells (VSMC) and
neoplastic human breast cancer cells (MCF-7). In both cell
types, MMG induced partial arrest in G2M and increased p14-
3-3, HSP70, HSP60 and p21 expression. Cells synchronized
by 24 h starvation reentered the normal cycle within 24 h if re-
leased in complete medium and exposed to normal gravity, but
not if exposed to MMG. Similarly, MMG prevented VSMC
and MCF-7 cells from overcoming growth arrest and re-synthe-
sizing DNA. This study shows that cells adjust their metabolic
rate in response to MMG.
2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
Microgravity induces adverse and metabolic eﬀects in ani-
mals, humans and cellular systems [1–4]. We have evaluated
the eﬀects of microgravity on cell proliferation, glucose uptake,
amino acid uptake and incorporation into proteins in neoplas-
tic human breast cancer cells (MCF-7) and normal murine vas-
cular smooth muscle cells (VSMC). Although these cells
originate from diﬀerent tissues and diﬀerent species and have
a distinct diﬀerentiation status, both are p53-positive and re-
quire similar culture conditions. In addition, both cell types
have insulin receptors, which suggest that their metabolic
activities depend on culture nutrients, including the insulin
normally present in fetal calf serum (FCS). As transformed
cells, MCF-7 require constant refurbishment to meet their en-
ergy requirements and are hence highly dependent on glucose
metabolism for growth, whereas muscle cells depend on ami-
no-acid metabolism (protein synthesis and breakdown). There-
fore, glucose uptake and amino acid uptake and utilization
studies conducted in these cells under conditions of micrograv-
ity may reveal derangements of metabolism induced by space-
related stress.
2. Materials and methods
2.1. Cell cultures
Human breast cancer MCF-7 cells were grown in DMEM-5% FCS+
at 37 C in a humidiﬁed atmosphere as previously reported [5]. VSMC
were harvested from aortas of young male rats (Sprague Dawley) by the
media explant technique and cultured in DMEM-10% FCS+ as de-
scribed elsewhere [6]. Serum starvation (in modiﬁedKrebs Ringer phos-
phate solution in the presence of 0.025% albumin) is designated
‘‘FCS’’. [3H]-thymidine, 2-deoxy-D-[14C]-glucose and [35S]-methionine
were purchased from Amersham (Milan, Italy). Concentration of pro-
teins extracted from cells was measured as according to Bradford [7].
2.2. Modeled microgravity
Six ﬂasks containing 1.5 · 105 MCF-7 cells or VSMC, at time 0 were
ﬁlled with FCS+ media and capped. Three (MCF-7 or VSMC) ﬂasks
were placed in a temperature-controlled room (37 C) on a running
random positioning machine (RPM; Dutch Space, The Hague, NL);
the remaining three ﬂasks were fasten to the edge of the RPM and
served as controls (see below). Samples and controls were left to grow
for 48 h in modeled microgravity (MMG).
2.3. Normal gravity
Cells grown on the RPM are subjected to changes in gravity and
mechanical stress due to the vibration of the machine. Therefore, we
fasten the control ﬂasks to the edges of the RPM. All control cells con-
sidered hereafter are those subjected to mechanical stress only.
2.4. DNA synthesis, glucose uptake, methionine uptake and
incorporation into neo-synthesized proteins
2.4.1. DNA synthesis. These assays were carried as described previ-
ously [5]. MCF-7 or VSMC (normally 1.5 · 105 cells) were incubated
with 1 lCi/ml of [3H]-thymidine as detailed in the legends to Figs.
1B and 4, respectively, then rinsed three times with cold PBS, and ﬁxed
in cold 10% trichloroacetic (TCA) acid. The precipitates were washed
with ethanol and dried by evaporation. The precipitates were washed
and solubilized in NaOH: a portion was used to determine protein con-
centration [7]; the remaining part was neutralized with HCl and
counted by liquid scintillation. Incorporation was calculated as counts
per minute (cpm) per mg of protein and expressed as percentage of
control. Three separate experiments have performed. Each experiment
was done using triplicate samples.
2.4.2. Glucose uptake. VSMC andMCF-7 cells were plated at a den-
sity of 1.5 · 105 cells and grown inFCS+medium.Cells were cultured for
about 24 h, transferred to a temperature-controlled room(37 C)and ex-
posed to MMG in a RPM for 48 h. They were then washed and starved
for 5 h inmodiﬁedKrebsRinger phosphate solution. Incubation (37 C)
Abbreviations:MMG, modeled microgravity; VSMC, vascular smooth
muscle cells; FCS, fetal calf serum; RPM, random positioning mach-
ine; MCF-7, neoplastic human breast cancer cells; NG, normal gravity
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was continued for 30 min after the addition of 2-deoxy-D-[14C]-glucose
and 0.17 mM glucose as carrier [5]. Next, cells were washed and solubi-
lized in NaOH and the protein concentration determined [7]. Finally
[14C]-deoxy-glucose radioactivity was counted by liquid scintillation.
Uptake was calculated as counts per minute (cpm) per mg of protein
and expressed as percentage of control. Three separate experiments have
performed. Each experiment was done using triplicate samples.
2.4.3. Methionine uptake and incorporation. Amino acid uptake was
determined in triplicate by measuring the uptake of [35S]-methionine
under normal gravity (NG) or MMG. After 36 h of MMG, cells were
removed from the RPM, washed, repositioned on the RPM, and
starved for 12 h with modiﬁed Krebs Ringer phosphate solution in
the presence of 0.05% albumin. Incubation (37 C) was continued for
30 min after the addition of [35S]-methionine (12.5 lCi/ﬂask). Next,
cells were thoroughly washed and solubilized in NaOH. The solution
was divided in three parts: a portion was used to determine protein
concentration [7], a portion was used to count total radioactivity (free
plus incorporated into proteins), a portion was used to measure pro-
tein-associated radioactivity after precipitation with TCA as described
elsewhere [8]. Results (counts per minute per mg of total protein) are
expressed as percentage of controls. Three similar experiments have
performed. Each experiment was done using triplicate samples.
2.5. Statistical analysis and presentation of data
Thymidine incorporation, methionine incorporation/uptake and
glucose uptake were expressed as % of respective controls to allow
the results of multiple experiments to be pooled and analyzed collec-
tively. Statistical signiﬁcance was estimated with the T-test. A P value
of less than 0.05 was considered statistically signiﬁcant.
Fig. 1. Panel a: MCF-7 cells (left) and VSMC (right) after 48 h of growth in NG and MMG. Panel b: Incorporation of [3H]-thymidine into DNA in
MCF-7 (left) and VSMC cells (right) exposed to MMG (close bars) and NG (open bars). Panels c and d: [35S]-methionine uptake and TCA-
precipitable material in MCF-7 (left) and VSMC cells (right) exposed to NG and MMG. Panel e: Uptake of 2-deoxy-[14C]-glucose in MCF-7 (left)
and VSMC (right) exposed to NG and MMG. Data are calculated by dividing the measured cpm per mg of protein and were expressed as % of
respective controls to allow the results of three experiments to be pooled and analyzed collectively. Statistical signiﬁcance in each experiment was
estimated with the t test, where P < 0.05 was considered statistically signiﬁcant.
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2.6. Flow cytometry – polyacrylamide gel electrophoresis and Western
blotting
At least 20000 events were collected for each sample. Samples pre-
pared as described by Crescenzi et al. [5] were routinely run in quadru-
plicate in an Excalibur Cytoﬂuorimeter (Becton Dickinson, Mountain
View, CA).
Total cell protein preparations, the materials and the detailed proce-
dure used for electrophoresis and Western blotting (WB) on nitrocellu-
lose ﬁlters, including the antibodies (primary and secondary) are as
previously reported [9]. In brief, after staining with Red Ponceau, suit-
able ﬁlters (i.e., those displaying a uniform level of staining in all lines)
were developed using an electro chemiluminescent WB detection re-
agent (Amersham) and quantiﬁed by scanning with a Discover Phar-
macia scanner equipped with a Sun Spark Classic Workstation. The
protein extracts, obtained by three ﬂasks were individually analyzed
by WB. Results are representative of three experiments.
2.7. Cell starvation, cycle arrest and recovery
Dishes containing 4 · 104 MCF-7 or VSMC cells were incubated
for 24 h at 37 C in 7 ml of complete medium. 24 h after attachment,
cells were washed and starved with modiﬁed Krebs Ringer phosphate
solution in the presence of 0.05% albumin for 24 h, at which time the
cell cycle was arrested. To determine the time required for cells to reen-
ter the cycle, cell cycle arrested cells were released in complete medium
and analyzed by cytoﬂuorimetry at 4, 8, 12 and 24 h. The eﬀect of
MMG on MCF-7 and VSMCs capacity to reenter the cycle, was esti-
mated by cytoﬂuorimetry, whereas the recovery of original prolifera-
tion rate, was evaluated by [3H]-thymidine incorporation experiments.
Cell cycle. Recovery after cell synchronization. Synchronized MCF-7
cells (seeded at a density of 1.5 · 105 cells/ﬂask) were obtained by
starvation in FCS medium. Thirty-six hours later, ﬂasks were
drained, reﬁlled with FCS+ medium, divided into two groups of three
ﬂasks each and exposed, respectively, to MMG or NG (controls) for
24 h. Cells were then ﬁxed and analyzed by cytoﬂuorimetry.
[3H]-thymidine incorporation. Recovery from cell synchronization. To
evaluate recovery from cell synchronization, six ﬂasks containing
2.0 · 105 attachedMCF-7 cells (time 0) were starved for 30 h by expo-
sure to FCS for 24 h. Once cells were synchronized, FCSmediumwas
replaced with FCS+medium containing 1 lCi/ml [3H]-thymidine. Three
ﬂasks were kept under NG, and three were put on the RPM, and incor-
poration was measured 15 h later. In a diﬀerent experiment, six ﬂasks
containing 2.0 · 105 VSMC cells were released in FCS and exposed
to MMG for 24 h. Cells were then released in FCS+medium containing
1 lCi/ml [3H]-thymidine, divided in two groups (three in NG and three
in MMG) and incubated for an additional 10 h before ﬁnal assessment
of thymidine incorporation. Each experiment, with MCF-7 and VSMC
was performed twice, in identical conditions as above.
3. Results and discussion
We have comparatively analyzed two cell lines, namely
VSMC (normal) and MCF-7 (transformed) cells to understand
how and to what extent weightlessness alters cellular properties
Table 1
Cell cycle of MCF-7 cells and VSMC exposed to NG and to MMG for
24 h
MCF-7 VSMC
NG MMG NG MMG
G0/1 63.4 ± 0.14 64.4 ± 4.0 70.4 ± 1.5 67.5 ± 1.5
S 27.7 ± 1.4 18.4 ± 2.5 23.7 ± 1.34 17.7 ± 2.2
G2/M 8.9 ± 1.5 17.2 ± 2.8 5.9 ± 0.14 14.8 ± 0.7
Average of three measurements.
Fig. 2. Each histogram, obtained by digital densitometry, compares the expression of the marked protein in MMG (closed bars) versus the NG
conditions (controls, open bars). Density of controls was arbitrarily set at 100. Upper panel refers to MCF-7 cells; lower panel to VSMC cells. Filter
staining with Red Ponceau has been used as indicator of uniform protein transfer, while actin (not shown), has been used as loading control. The
representative WB inserts show the proﬁle of the indicated proteins in MMG and NG conditions. Although multiple experiments and scans have
been performed, all data may be considered only denotative of an apparent increasing (left), decreasing (center) or unchanging (right) trend in the
particular protein expression.
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including basal proliferation rate (thymidine incorporation),
glucose uptake and methionine uptake/incorporation, cell cy-
cle proﬁles and the expression of several proteins.
3.1. Cell growth and proliferation
Proliferation was much lower in MCF-7 cells and in VSMC
exposed to MMG versus NG (Fig. 1, panel a). Moreover, [3H]-
thymidine incorporation was signiﬁcantly (P < 0.05) lower in
MCF-7 cells (70%) and in VSMC (50%) exposed to
MMG (Fig. 1, panel b). As found in free-ﬂoating Jurkat cells
[10], MMG caused both cell types to slightly accumulate in G2/
M (Table 1). This partial remodeling of the cell cycle was asso-
ciated with reduced cell proliferation. Prolonged MCF-7 mito-
sis during MMG is not a new ﬁnding and has been attributed
to weightlessness-induced alteration of microtubules [4]. Also
Meyers et al. [11] found that MMG alters proliferation rate,
and reported that MMG, by decreasing integrin/MAPK sig-
naling, contributes to reduced osteoblastogenesis during diﬀer-
entiation of human mesenchymal stem cells. Similarly, Plett
et al. [12] demonstrated that MMG causes alterations of
human hematopoietic progenitor cells.
3.2. Cellular metabolic activity
Fig. 1 shows also the eﬀects in both MCF-7 and VSMC cells
of MMG as compared to NG on some metabolic cellular activ-
ities. It appears that the incorporation of methionine into TCA-
precipitable materials (panels c), its cellular uptake (panels d)
and the deoxy-glucose uptake (panels e), are neatly reduced.
All the diﬀerences noted were statistically signiﬁcant (P < 0.05).
3.3. Protein expression
Protein expression has been quantitated by digital densitom-
etry of three independent experiments. As may be noticed by
the bars in Fig. 2 (see additional details in the legend),
MMG-exposed MCF-7 cells (upper panel) express increased
levels of HSP60 (50%), Bcl-XL (35%) and p14-3-3 protein
(30%); even p21 and HSP70 appear to be elevated, although
to a lesser extent. Densitometry indicated possibly lower levels
of both Cdk-1 and -2 (15%). Similarly MMG did not (or very
imperceptibly) aﬀect the expression of p53, Bax, Bcl-2, p27 and
Cyclins or PARP (not shown). As shown in lower panel of the
same ﬁgure, MMG-exposed VSMC cells appear to express in-
creased levels of HSP60 (>50%) and, to a lesser extent, of p21
(25%), HSP70 (20%), p14-3-3 (20%) and Bcl-XL (15%).
Cyclin kinases appear to decrease of 20%, while cyclins, p53,
p27, Bax and also Bcl-2 (which indeed is already undetectable
in control VSMC cells) appear to remain unchanged. Even in
this case, PARP was not aﬀected (not shown).
The increased expression of the constitutive proteins HSP-
60, in particular, and, to a lesser extent, HSP-70 is obscure,
Fig. 3. MCF-7 growing in FCS+ in NG (a); cells starved in FCS for 24 h under NG (b); cells starved for 24 h (as before) and released in FCS+ for a
further 24 h under NG (c); cells starved for 24 h and released in FCS+ for a further 24 h under MMG (d). Data shown are representative of triplicate
samples.
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although the two proteins may work in tandem to facilitate the
refolding process after damage [13]. It is possible that MMG
drives cells beyond their normal activity. This metabolic dis-
turbance, accompanied by a modest, albeit reproducible in-
crease in p21 and Bcl-XL expressions, negatively inﬂuences
cell proliferation. Similarly, MMG aﬀected appreciably the
expression of p14-3-3 (especially in MCF-7). This protein is
important for such vital regulatory processes as mitogenic sig-
nal transduction and cell cycle control [14]. In agreement with
the cell cycle proﬁles, which lacked signs of apoptosis, the pro-
ﬁles of the pro-apoptotic proteins BAX and PARP (not
shown) are unchanged as compared to controls.
Since digital densitometry integrates bands produced on
ﬁlms by chemiluminescent signals, which are intrinsically
semi-quantitative, the data should be regarded with some cau-
tion: nonetheless, they are not in contrast with our metabolic
and cytoﬂuorimetric ﬁndings (see below) and previous obser-
vations made by others [10,11].
3.4. Effect of MMG on synchronized cells
We used two strategies, both based on a ‘‘stop and go’’ ap-
proach, to determine whether MMG aﬀects proliferation rate.
This requires preliminary synchronization of cells by serum
starvation (stop) followed by re-nourishing of cells in FCS-con-
taining medium (go) in MMG or NG (Fig. 3, panel a, controls).
In one strategy we examined the original cell cycle proﬁle, and
in the other we evaluated restoration of the propensity to syn-
thesize DNA by examining [3H]-thymidine incorporation.
Cell cycle. Exposure of MCF-7 cells for 24 h to a FCS solu-
tion caused cell cycle arrest and complete (92%) synchroniza-
tion in G1 (Fig. 3, panel b). Upon release in FCS
+ medium,
these cells resumed normal cycling activity, and the original
proﬁles were restored after exposure to NG for 24 h (Fig. 3,
panel c). This was not the case of cells exposed to MMG for
24 h. In this case >90% of cells arrested by starvation in G1
did not progress (Fig. 3, panel d). This result indicates that
MMG can hamper the normal cycling of the malignant fast-
proliferating MCF-7.
[3H]-thymidine incorporation. To determine whether MMG
aﬀects DNA synthesis, we examined fast growing MCF-7 cells
and the normal slow proliferating VSMC. MCF-7 cells were
synchronized by simple starvation for 24 in NG, whereas the
slow proliferating VSMC cells were synchronized by starving
cells exposed to MMG for 24 h.
The best estimates of two experiments, based on the
weighted average of the determinations are reported in
Fig. 4, indicated that DNA synthesis was reduced by 4-fold
(MCF-7, left panel) and 2-fold (VSMC, right panel) in cells
exposed to MMG. In both cases, the diﬀerences of the means
are statistically signiﬁcant (P < 0.05).
In conclusion, our results show that MMG alters the cytoﬂu-
orimetric proﬁle and slows down fundamental metabolic activ-
ities (glucose uptake, methionine uptake/incorporation and
thymidine incorporation) in normal and transformed cells.
MMG did not aﬀect signiﬁcantly the expression of most pro-
teins that are related to the cell cycle and apoptosis, whereas
it altered the expression of stress proteins. The large increase
in the expression of HSP-60 and a minor increase in HSP-70
and 14-3-3 protein, suggest that transformed and normal cell
lines are able to ‘‘sense’’ the altered conditions of gravity. We
hypothesize that cells respond to stress by putting the prolifer-
ative and metabolic machinery on ‘‘stand by’’. MMG-pro-
moted quiescence is demonstrated in both cell lines by the cell
cycle proﬁling data and thymidine incorporation after synchro-
nization. MMG alters the hydrodynamics of nutrient ﬂuids
(buoyancy and convection), that, in turn, aﬀects the cell envi-
ronment and cell–cell interactions. These changes, responsible
for previously reported alterations in cell morphology [4,10]
and in metabolic activity in animals [1] may explain also our re-
sults. It remains to be established whether or not these eﬀects are
fully or partially reversible, if are transient and if they may rep-
resent potential danger to human health in space, particularly in
the presence of other hazards such as cosmic radiation.
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Abstract
We compared the effects of monotherapy (photodynamic
therapy or chemotherapy) versus combination therapy
(photodynamic therapy plus a specific drug) on the non–
small cell lung cancer cell line H1299. Our aim was to
evaluate whether the additive/synergistic effects of
combination treatment were such that the cytostatic dose
could be reduced without affecting treatment efficacy.
Photodynamic therapy was done by irradiating Photofrin-
preloaded H1299 p53/p16-null cells with a halogen lamp
equipped with a bandpass filter. The cytotoxic drugs used
were cis-diammine-dichloroplatinum [II] (CDDP or cisplatin)
and 2V,2V-difluoro-2V-deoxycytidine (gemcitabine). Vari-
ous treatment combinations yielded therapeutic effects
(trypan blue dye exclusion test) ranging from additive to
clearly synergistic, the most effective being a combination
of photodynamic therapy and CDDP. To gain insight into
the cellular response mechanisms underlying favorable
outcomes, we analyzed the H1299 cell cycle profiles and
the expression patterns of several key proteins after
monotherapy. In our conditions, we found that photody-
namic therapy with Photofrin targeted G0-G1 cells, thereby
causing cells to accumulate in S phase. In contrast, low-
dose CDDP killed cells in S phase, thereby causing an
accumulation of G0-G1 cells (and increased p21 expres-
sion). Like photodynamic therapy, low-dose gemcitabine
targeted G0-G1 cells, which caused a massive accumula-
tion of cells in S phase (and increased cyclin A expression).
Although we observed therapeutic reinforcement with
both drugs and photodynamic therapy, reinforcement was
more pronounced when the drug (CDDP) and photody-
namic therapy exert disjointed phase-related cytotoxic
activity. Thus, if photodynamic therapy is appropriately
tuned, the dose of the cytostatic drug can be reduced
without compromising the therapeutic response. [Mol
Cancer Ther 2006;5(3):776–85]
Introduction
Although chemotherapy is the leading treatment for most
types and stages of cancers, photodynamic therapy is an
effective anticancer procedure for selected tumors (1). This
procedure involves administration of a tumor-localizing
photosensitizing agent that when activated by light of a
specific wavelength mediates cell destruction via the
production of singlet oxygen. Photodynamic therapy has
been shown to have few or no side effects in patients with
Barrett’s esophagus (high-grade dysplasia and early carci-
noma) and in selected cases of early squamous cell
carcinoma (2). One of the most widely used photosensitiz-
ing drugs is the hematoporphyrin-derivative Photofrin.
This nontoxic substance has been used for photodynamic
therapy for f8 years and is the only one widely approved
for human therapy. On exposure of Photofrin-loaded cells
to visible light, intracellular toxic oxygen species (singlet
oxygen, 1O2) are generated that can trigger cell apoptosis or
necrosis (3, 4).
Anticancer drugs target several cellular components and
activate responses that go from cell repair to cell death.
However, chemotherapy is effective only at high doses,
because, at low doses, tumor cells may repair damage and
resume their original high proliferation rate (5). Cis-
diammine-dichloroplatinum [II] (CDDP or cisplatin) and
2V,2V-difluoro-2V-deoxycytidine (gemcitabine) are widely
used in the management of various cancers. By forming
adducts in DNA, CDDP inhibits DNA replication and chain
elongation, which accounts for its antineoplastic activity. In
clinical practice, CDDP is often combined with other drugs.
Synergy between CDDP and other chemotherapeutic
agents occurs by various pathways: increased intracellular
drug accumulation, enhanced binding to DNA, and
decreased DNA repair (6). Gemcitabine is a deoxycytidine
analogue that is effective against solid tumors, including
non–small cell lung cancer. After transport into the cell,
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gemcitabine requires phosphorylation by deoxycytidine
kinase to exert biological activity (7, 8). The enzyme
responsible for this reaction is also the rate-limiting step
in gemcitabine activation (8). It has been suggested that
the combination of photodynamic therapy and convention-
al cancer treatments may become a workable anticancer
strategy (9).
The aim of our study was to identify photodynamic
therapy/chemotherapy combinations in which the dose of
the most toxic compound could be decreased without a loss
of efficacy. To this aim, we examined the response of H1299
human lung metastatic non–small cell lung cancer cells
(cell viability, cell cycle, and protein expression) to
moderately toxic doses of CDDP or gemcitabine with
Photofrin/photodynamic therapy, administered separately
and in appropriate combinations.
Materials andMethods
Cell Cultures
The NCI-H1299 human non–small cell lung cancer cell
line was obtained from American Type Culture Collection
(Rockville, MD). They were cultured in RPMI 1640, 2
mmol/L L-glutamine, 10 mmol/L HEPES, 1 mmol/L
sodium pyruvate, 4,500 mg/L glucose, 1,500 mg/L sodium
bicarbonate, 100 Ag/mL streptomycin, 100 units/mL peni-
cillin, and 10% FCS. The medium was changed every 3 days.
All media and cell culture reagents were purchased from
Life Technologies (San Giuliano Milanese, Italy). NCI-H1299
cells are p53/ and p16/. All treatments, individual
and in combination, were done in triplicate samples in tissue
culture dishes (35 mm) in which 5  104 cells were routinely
seeded. A larger number of cells (4  105) were seeded for
cell cycle measurements and for protein extraction for
Western blotting purposes. The effects of monotherapy with
drugs or photodynamic therapy or combined therapy (drugs
+ photodynamic therapy) were evaluated (a) by trypan blue
assays (to check residual cell viability), (b) by analyzing cell
cycle profiles (to determine the cell distribution in the
various conditions), and (c) by analyzing expression patterns
(Western blots) of specific proteins involved in the control of
cell growth and survival.
Cytotoxic Drugs
CDDP was obtained from Sigma-Aldrich Srl (Milan,
Italy). A stock solution was obtained by dissolving CDDP
in DMSO to obtain a final concentration of 40 mmol/L.
Aliquots were stored at 20jC until used. Gemcitabine
chlorhydrate (Gemzar) was supplied as dry powder by
Eli Lilly SpA (Sesto Fiorentino, Italy). A stock solution
(67 mmol/L) was obtained by dissolving gemcitabine in an
isotonic solution (0.9% NaCl). Aliquots were stored at
20jC until used.
Photosensitizer
The Photofrin (the hematoporphyrin derivative Porfimer
sodium) used in this work was supplied as freeze-dried
powder (lot no. 162A6-06; Axcan Pharma, Mont-Saint-
Hilaire, Quebec, Canada). Its absorption spectrum consists
of various peaks within the visible region. A Photofrin
stock solution was obtained by dissolving the powder in
water containing 5% glucose to obtain a final concentration
of 2.5 mg/mL. This solution was stored in aliquots at
20jC in the dark. Before measurements, appropriate
aliquots of this solution were diluted to the desired
concentration. Except for ‘‘dark toxicity assays,’’ Photofrin
was always used at a concentration of 2.5 Ag/mL. All
treatments involving Photofrin were done on triplicate.
Cells were exposed to 2.5 Ag/mL Photofrin for 16 hours
before irradiation.
Chemotherapy and Chemotherapy Schedule
Usually, 5  104 H1299 cells were seeded in 35-mm tissue
culture dishes and exposed to the cytotoxic substances
(individual or combined with photodynamic therapy) 24
hours later. This procedure was carried out in triplicate.
Normally, 4  105 cells were used for cell cycle measure-
ments and protein extraction for Western blotting. To
obtain CDDP/gemcitabine dose-response curves, culture
dishes were treated with CDDP (2.5–12 Amol/L) or
gemcitabine (2–12 nmol/L) and kept at 37jC for 24 hours.
After incubation, cells were washed and released into fresh
medium. Cell viability was evaluated with the trypan blue
assay (as detailed in ref. 10) 24 hours later, counting
between 15 and 30 cells per field. Two sets of data were
collected for each drug. In combination experiments, after
incubation with the drug (0–24 hours) and Photofrin (8–24
hours), cells were washed, placed in a colorless saline
solution (Hank’s), and immediately irradiated. After
irradiation, cells were placed in fresh complete medium,
and cells negative to trypan blue staining were counted 24
hours later (see Fig. 1). Residual viability was expressed as
percentage of trypan blue–negative cells versus untreated
controls.
PhotodynamicTherapy and Photodynamic Therapy
Schedule
Cells were irradiated by a broadband light delivered with
a PTL-Penta apparatus (Teclas, Sorengo, Switzerland). This
apparatus consists of a halogen lamp (Osram 250 W, 24 V
Osram, Munich, Germany) equipped with a bandpass filter
(>80% transmittance in the 510 to 590 nm spectral region;
bandwidth f40 nm at 50% of the peak) corresponding
approximately to one of the Photofrin absorption peaks.
The emission spectrum was measured with a Macam
SR9910 spectroradiometer (Macam Photometrics, Living-
ston, Scotland, United Kingdom). The light was delivered
through an 8-mm bundle of optical fibers placed at a
distance from the cell plates that ensures uniform illumi-
nation of the entire cell monolayer. The fluence rate at the
level of the cell monolayer was fixed at 6 mW/cm2 and
irradiations were done with light doses of up to 1.8 J/cm2.
We invariably used a Photofrin concentration of 2.5 Ag/mL.
At a fluence of 0.54 J/cm2, photodynamic therapy mono-
therapy reduced H1299 cell viability to f50% that of
treated but not irradiated cells (controls). Doses between
0.18 and 0.54 J/cm2 were used in the combination experi-
ments. Because only a few cells survived combined therapy
with fluences >0.54 J/cm2, higher fluences were not
considered. In brief, after incubation, cells were washed
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extensively, placed in colorless Hank’s solution, exposed to
light, and analyzed by cytofluorimetry either immediately
or after exposure to fresh medium for a further 24 hours.
Similarly, cell extracts obtained f3 or 24 hours after
irradiation were used to obtain protein profiles (Western
blots). Residual cell viability was assessed by trypan blue
assay after cells have been placed in fresh medium for 24
hours (Fig. 1).
Flow Cytometry
Dishes (10 cm) containing 4  105 H1299 cells were
incubated for 24 hours at 37jC in 7 mL complete medium
(controls) or in medium supplemented with Photofrin (2.5
Ag/mL) alone or associated with CDDP (2.5 Amol/L) or
gemcitabine (4 nmol/L). Cells were exposed to photody-
namic therapy as described above and were then detached
from the dishes by trypsinization, suspended in serum-
rich medium, centrifuged, washed twice with 1 mL PBS,
and resuspended for storage (20jC) in 95% ethanol.
Before analysis, fixed cells were washed twice, centri-
fuged, and resuspended in 1 mL PBS containing 1 Ag
RNase and 100 Ag propidium iodide (11). Samples were
stored in the dark for 20 minutes at room temperature
before final readings. The cellular orange fluorescence of
propidium iodide was detected in a linear scale using a
flow cytometer (FACScan, Becton Dickinson, Mountain
View, CA) equipped with an excitation laser line at 488
nm. About 30,000 events (i.e., fluorescence readings,
corresponding to not less than 20,000 cells) were recorded
for each sample. The cell cycle was examined after
monotherapy and combined treatment at the indicated
times (see Fig. 1). Data were analyzed with ModFit/LT
(Verity Software, Topsham, ME).
Median Effect Analysis
We used the median effect analysis (12) together with the
combination index (CI) to ascertain synergy and the
additivity/antagonism of photodynamic therapy and che-
motherapy. The median effect analysis derives directly
from the mass action law and does not depend on a
reaction mechanism. The reference equation is Fa / Fu =
(D / Dm) * m , where Fa is the affected fraction, Fu is the
unaffected fraction, D is the dose, Dm is the median dose
(50%, for instance), and m is a coefficient related to the
shape of the dose-response curve (m = 1, hyperbolic; m > 1,
sigmoidal; m < 1, negatively sigmoidal). The shape is easily
determined from the dose-effect curve from which Dm is
directly estimated. The CI for treatments that are not
mutually exclusive (i.e., that unequivocally have different
modes of action) can be calculated by (13): CI = (D)1 / (Dx)1
+ (D)2 / (Dx)2 + [(D)1(D)2] / [(Dx)1(Dx)2], in which (D)n is
the dose of the nth drug (or of light) needed to obtain a
given effect in the combination and (Dx)n is the dose of the
same drug (or light) necessary to obtain the same effect
when used alone. Chou and Talalay (12) defined synergism
as a more than expected additive effect, where the additive
effect is designated CI equal to unity. Thus, for mutually
exclusive agents that have totally independent modes of
action, CI < 1, CI = 1, and CI > 1 indicate synergy, additive
effect, and antagonism, respectively. We thus constructed
several dose-response curves at a constant fluence and at a
constant drug concentration.
Western Blot Analysis
Total cell protein preparations were obtained by lysing
cells in 50 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, 1%
NP40, 0.1% Triton, 2 mmol/L EDTA, 10 Ag/mL aprotinin,
and 100 Ag/mL phenylmethylsulfonyl fluoride. Protein
concentration was routinely measured with the Bio-Rad
protein assay (14). Polyacrylamide gels (10–15%) were
prepared essentially as described by Laemmli (15). Molec-
ular weight standards were from New England Biolabs
(Beverly, MA). Proteins separated on the polyacrylamide
gels were blotted onto nitrocellulose filters (Hybond-C
pure, Amersham Italia, Milan, Italy). Filters were washed
and stained with specific primary antibodies and then with
secondary antisera conjugated with horseradish peroxidase
(Bio-Rad; diluted 1:2,000). Filters were developed using an
electrochemiluminescent Western blotting detection
reagent (Amersham Italia) and quantified by scanning
with a Discover Pharmacia scanner equipped with a Sun
Spark Classic Workstation. The anti-Bcl-2 (100), Bcl-XL
(S-18), Bax (N-20), p21 Cip1 (C-19), cyclin A (C-19), Cdk2
(M2), HSP60 (N-20), HSP70 (K-20), and actin (C-2) anti-
bodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-caspase-3 (Ab-3), human (mouse), was from
Calbiochem (San Diego, CA).
Results and Discussion
The metastatic non–small cell lung cancer H1299 carcino-
ma cell line does not express p53 or p16 INK4a. Although
sensitivity to photodynamic therapy is not altered in
human tumor cells after p53 abrogation (16), inactivation
of the p53 and p16 INK4a pathways does not completely
abrogate stress responses in carcinoma cells (17).
We evaluated if Photofrin/photodynamic therapy plus
CDDP or gemcitabine induces an additive or even a
synergistic effect, our aim being to determine whether the
Figure 1. Single-agent and combination treatment schedule. For single-
agent CDDP or gemcitabine treatments, cells were incubated with
chemotherapeutic drugs for 8, 12, or 24 h, washed, and analyzed
immediately and after 3 h. Cells exposed to drugs for 24 h were also
analyzed 24 h after washing and release into fresh medium. Before
photodynamic therapy, cells were incubated for 16 h with Photofrin in the
dark. For combination treatments, cells were treated with CDDP or
gemcitabine at prefixed concentrations, and Photofrin was added 8 h later.
The samples were washed and analyzed immediately or released in fresh
medium and analyzed 24 h later. CC, cell cycle; WB, Western blot; TBa,
trypan blue assay; star, light turned on.
Photofrin/Photodynamic Therapy and Antineoplastic Drugs778
Mol Cancer Ther 2006;5(3). March 2006
dose of the cytostatic drug can be reduced. To identify the
most effective doses of the components of combination
therapy, we analyzed (a) the response of Photofrin-treated
H1299 cells to increasing light doses, (b) the response of
cells to increasing concentrations of CDDP or gemcitabine,
and (c) the response of cells to combined therapy in
selected conditions.
We first tested low CDDP (V2.5 Amol/L) and gemcitabine
(between 2 and 8 nmol/L) concentrations and mild
photodynamic therapy conditions (Photofrin concentration,
2.5 Ag/mL; light fluence, 0.18–0.54 J/cm2). However, we
focused on a concentration of 2.5 Amol/L for CDDP and
4 nmol/L for gemcitabine, and the fluence of choice was
0.54 J/cm2. These drug concentrations caused a near
50% mortality when used alone. Higher concentrations
(>5 Amol/L CDDP or >8 nmol/L gemcitabine) were not
compatible with photodynamic therapy at a fluence of 0.54
J/cm2, because no (CDDP) or only a few cells (gemcitabine)
survived this combined treatment. Fluctuations of the
lamp, which make it difficult to measure fluence accurately
within the short irradiation time (<30 seconds), precluded
the use of lower fluences (<0.2 J/cm2).
We evaluated Photofrin-induced toxicity in the absence
of light (‘‘dark toxicity’’) in 5  104 cells seeded in 35-mm
tissue culture dishes and treated 24 hours later with 0, 2.5,
4, 8, 10, and 25 Ag/mL Photofrin. Sixteen hours later, cell
viability was evaluated by the trypan blue and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assays (data not shown). We compared the viability of
normally growing cells (100%) versus Photofrin-treated but
not light-sensitized cells. Cell viability decreased in a dose-
dependent fashion starting with 3.0 Ag/mL Photofrin, and
25 Ag/mL Photofrin reduced cell viability by a factor >5.
With 2.5 Ag/mL Photofrin, toxicity did not exceed 5%;
hence, we used this dose in the photodynamic therapy
experiments.
IndividualTreatments
Because photodynamic therapy was applied to cells
treated for 24 hours with CDDP or gemcitabine, we first
determined the cycle stage of cells on irradiation. To this
end, we incubated H1299 cells with 4 nmol/L gemcitabine
or 2.5 Amol/L CDDP for 0 (controls), 8, 12, and 24 hours.
The cells were then washed and immediately fixed for
cytofluorimetry. Gemcitabine rapidly induced depletion of
G2-M cells and hence an accumulation of G1 cells; 12 hours
later, almost all cells were in S phase (Table 1). Therefore,
when photodynamic therapy was applied, gemcitabine-
exposed (4 nmol/L) cells were mostly in S phase. CDDP,
on the contrary, caused cell accumulation in S phase
followed by cell synchronization in G1. Therefore, on
photodynamic therapy, the S and G2-M phases were
partially emptied. After cells were withdrawn from CDDP-
or gemcitabine-containing medium and placed in complete
medium, they reentered the normal cycle within 24 hours
(see also Fig. 1).
The two cytostatic drugs dose-dependently affected cell
viability (Fig. 2). At 2.5 Amol/L, CDDP reduced cell via-
bility byf50% versus controls, and with 12 Amol/L CDDP,
cell viability approached 0. Similarly, 4 nmol/L gemcita-
bine reduced cell viability by f50%, and 10 nmol/L
gemcitabine reduced it to <20% of control values. Cell
viability was not completely abolished even at much higher
gemcitabine concentrations (data not shown).
The photodynamic therapy experiments were done in
triplicate with 5  104 H1299 cells seeded in 35-mm tissue
culture dishes. Twenty-four hours after seeding, the cells
were incubated with Photofrin (2.5 Ag/mL) for 16 hours,
washed thrice with HBSS, and irradiated with increasing
doses of light (see below). Cells were released into drug-
free complete medium and left to grow forf3 or 24 hours.
At nontoxic Photofrin concentrations (i.e., 2.5 Ag/mL),
photodynamic therapy dose-dependently affected the
magnitude of cell injury (Fig. 3). When light fluence
increased from 0 to f1.40 J/cm2, cell viability decreased
proportionally. No cells survived a fluence of 1.80 J/cm2
(data not shown). At 0.54 J/cm2, cell viability was reduced
by f50%. We used this sublethal dose in combination
experiments with cytotoxic drugs. Unless indicated other-
wise, all experiments reported hereafter were conducted
with cells incubated for 16 hours with 2.5 Ag/mL Photofrin
and irradiated with a light fluence of 0.54 J/cm2.
Combined Effects
Because we aimed at using the lowest drug concentration
possible, we tested CDDP concentrations between 0.5 and
2.5 Amol/L and gemcitabine concentrations between 2 and
8 nmol/L while maintaining fluence at 0.54 J/cm2. Very
few cells treated with low concentrations of CDDP or
gemcitabine survived fluences above 0.54 J/cm2. Howev-
er, within the concentration range tested, gemcitabine did
not kill all H1299 cells (Fig. 2). Thus, for gemcitabine,
we evaluated the effects caused by a fixed fluence on
cells incubated with drug concentrations between 2 and
8 nmol/L and the effects caused by fixed drug concen-
trations (i.e., 4 and 8 nmol/L) and light fluences of 0.18,
0.28, 0.36, and 0.54 J/cm2. We evaluated the efficacy of
combined therapy by calculating the CI as detailed in the
next paragraph and as reported in Table 2A (fixed fluence,
0.54 J/cm2; CDDP between 0.25 and 2.50 Amol/L), Table 2B
(fixed fluence, 0.28 J/cm2; gemcitabine between 2 and
8 nmol/L), and Table 2C (fluence between 0.18 and 0.54
J/cm2, gemcitabine 4 nmol/L). The most striking results
were obtained with a light fluence of 0.54 J/cm2 combined
Table 1. Cytofluorimetric profiles of H1299 cells at 0 and 8, 12,
and 24 hours of treatment with CDDP (2.5 Mmol/L) or
gemcitabine (4 nmol/L)
Phase Control CDDP (2.5 Amol/L) Gemcitabine (4 nmol/L)
0 h 8 h 12 h 24 h 8 h 12 h 24 h
G0-G1 47.3 40.2 39.0 64.9 57.6 56.5 18.1
S 39.4 51.0 51.3 28.5 42.4 43.4 81.9
G2-M 13.3 8.8 9.7 6.6 0 0.1 0
NOTE: Values are expressed as percent. Note the specific effects at 24 hours
(bold).
Molecular Cancer Therapeutics 779
Mol Cancer Ther 2006;5(3). March 2006
with 2.5 Amol/L CDDP or 4 nmol/L gemcitabine.
Individually, photodynamic therapy, CDDP, and gemci-
tabine reduced cell viability to 50 F 7%, whereas
photodynamic therapy combined with CDDP or gemcita-
bine reduced cell viability to 8 F 2% and 14 F 4%,
respectively (Fig. 4).
Median Effect Analysis
Using the Chou and Talalay method (12) and the equa-
tions developed by Mack et al. (13), we calculated the CI and
show that the effects of combined therapy at a fixed light
fluence (0.54 J/cm2) are additive within the range of CDDP
concentrations used. These effects changed from possibly
synergistic to explicitly synergistic at CDDP concentrations
above 2.0 Amol/L (Table 2A). Differently, the overall effect
remained additive with gemcitabine plus photodynamic
therapy. The CI was 1 both when the drug was increased
from 2 to 8 nmol/L and the light fluence was fixed at 0.28 J/
cm2 (Table 2B) and with gemcitabine fixed at 4 nmol/L and
light fluences were between 0.18 and 0.54 J/cm2 (Table 2C).
Cell Cycle and Protein Expression
To investigate the mechanisms by which Photofrin/
photodynamic therapy and the cytotoxic drugs exert their
effects when used alone or in combination, we analyzed
the H1299 cell cycle and the expression levels of the Bcl-2,
Bcl-XL, Bax, caspase-3, p21, pRb, cyclin A, Cdk2, HSP60,
and HSP70 proteins (Fig. 5), which are related to apoptosis,
cell cycle, and stress. Figure 1 shows the schedules of
single-agent and combination treatments. The cytofluori-
metric profiles obtained after the release of cells in drug-
free medium for an additional 24 hours represents the
distribution that would be found in the event of ineffective
photodynamic therapy.
CDDP. Using cytofluorimetry, we examined the H1299
cell cycle after 0, 8, 12, and 24 hours of incubation with
2.5 Amol/L CDDP (Table 1). After 24 hours, cells have accu-
mulated in G0-G1 phase (see Table 1; Fig. 6) with a conse-
quent loss of cells (f50%; trypan blue assay) in S phase.
After exposure to CDDP for 24 hours, cells were released
into fresh medium forf3 and 24 hours. Synchronization in
S phase was sustained for the first 3 hours, whereas cells
approached the normal cycle at 24 hours (data not shown).
This observation implies that the arrest in S phase was
reversible. Protein expression studies (Western blot) support
this notion. In fact, p21 protein expression was enhanced
in H1299 cells exposed to 2.5 Amol/L CDDP for 24 hours
(Fig. 5A, lane 2). However, p21 expression returned to basal
levels within 24 hours (Fig. 5A, lane 5).
Surprisingly, although H1299 cells are p53 mutated
(/), p21 protein expression seemed to be up-regulated
at transcriptional level in the presence of CDDP. However,
the p21 gene is also regulated by p53-independent factors,
including growth promotion factors and differentiation-
associated transcription factors (18). Moreover, CDDP
concentration and incubation conditions may account for
cytofluorimetric profile changes in various cells. In fact,
whereas high CDDP concentrations cause cells to accumu-
late in the S-G2 phases (13, 19–21), low CDDP doses induce
Figure 2. Effect of increasing concentrations of CDDP (bottom curve ;
0–15 Amol/L) and gemcitabine (top curve ; 0–12 nmol/L) on the viability
of H1299 cells. Two sets of data from separate experiments are reported.
Cells were incubated at the indicated CDDP or gemcitabine concentrations
for 24 h, washed, and incubated for 24 h in fresh medium. Cell viability
was measured by counting cells negative to trypan staining. Residual
viability was expressed as percentage of untreated cells (controls).
Triangles and diamonds, CDDP; squares and circles, gemcitabine.
Points, average of three determinations; bars, SD.
Figure 3. H1299 cells were incubated in the dark for 16 h with Photofrin
(2.5, 4.0, 8, or 10 Ag/mL). Dark toxicity was low (<5%) with 2.5 Ag/mL
Photofrin and high with 4 to 10 Ag/mL (circles ). Cell viability on irradiation
was measured by the trypan blue exclusion test with a Photofrin
concentration of 2.5 Ag/mL. Points, average of three determinations;
bars, SD. PDT, photodynamic therapy.
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an increase in p21 expression unaccompanied by bromo-
deoxyuridine incorporation (21), which suggests an arrest
in G1. A G1 arrest has also been reported in other cell lines
at high CDDP concentrations (50 Amol/L) but with short-
term (2 hours) exposure (22). Also in our hands, 24-hour
incubation with CDDP concentrations as high as 8 Amol/L
caused cells to accumulate in G2 (from <14% at 2.5 Amol/L
to >31% at 8 Amol/L; data not shown). In conclusion,
Table 2. Monotherapy versus combined therapy: median effect analysis and CI
A. Comparison of monotherapy (photodynamic therapy or CDDP) versus combined therapy (photodynamic therapy and CDDP) at a
constant light fluence (CI < 1 indicates synergy)
Monotherapy Combined therapy
1 2 3 4 5 6 7
(Dx)1 Fluence
(J/cm2)
(Dx)2 CDDP
(Amol/L)
Observed effect
cell viability (%)
D1 fluence (J/cm
2) D2 CDDP
(Amol/L)
CI Combined effect
0 0 100 0.54 — — —
0.18 ND 82 — — —
0.36 1.5 68.5 — — —
0.54 2.5 50 0 1 Additive
0.61 3.0 45 0.25 1.02 Additive
0.73 4.0 36 0.50 0.96 Additive
0.81 1.5 33 1.00 1.04 Additive
0.99 5.0 25 1.50 0.90 Additive
1.08 6.0 20 2.00 0.85 Additive/synergistic
1.25 9.0 12 2.25 0.76 Synergistic
1.44 10.0 7 2.50 0.74 Synergistic
B. Comparison of monotherapy (photodynamic therapy or gemcitabine) versus combined therapy (photodynamic therapy and
gemcitabine) at a constant light fluence (CI = 1 indicates an additive effect)
Monotherapy Combined therapy
1 2 3 4 5 6 7
(Dx)1 Fluence
(J/cm2)
(Dx)2 Gemcitabine
(nmol/L)
Observed effect
cell viability (%)
D1 Fluence (J/cm
2) D2 Gemcitabine
(nmol/L)
CI Combined effect
0.28 1.5 80 0.28 0 1 —
0.38 2.0 72 2.0 1.03 Additive
0.60 5.5 44 4.0 1.06 Additive
0.80 8.0 30 6.0 0.97 Additive
0.92 12.5 22 8.0 0.99 Additive
C. Comparison of monotherapy (photodynamic therapy or gemcitabine) versus combined therapy (photodynamic therapy and
gemcitabine) at a constant gemcitabine concentration (CI = 1 indicates additivity)
Monotherapy Combined therapy
1 2 3 4 5 6 7
(Dx)1 Fluence
(J/cm2)
(Dx)2 Gemcitabine
(nmol/L)
Observed effect
cell viability (%)
D1 Fluence (J/cm
2) D2 Gemcitabine
(nmol/L)
CI Combined effect
0.54 4.0 50 0 4.0 1 —
0.65 6.0 41 0.18 1.05 Additive
0.72 6.5 37 0.28 1.01 Additive
0.98 11.0 21 0.36 0.99 Additive
1.2 14.5 15 0.54 0.98 Additive
NOTE: (Dx)1 and (Dx)2 are the doses of light or drug necessary to obtain a given effect when used alone; (D1) and (D2) are the doses of light and drug needed to
obtain the same effect when used in the combination. Column 3 shows the residual cell viability on irradiation at the indicated light fluences [column 1, (Dx)1]
or drug treatment at the indicated concentrations [column 2, (Dx )2], respectively. Columns 4 and 5 (D1 and D2) report the light fluences and drug
concentrations used in combination. Columns 6 and 7 show the CI and the type of effect ensuing from combination. Monotherapy data in Table 2A–C are
taken from Figs. 2 and 3, which provide the relative SD. Combined therapy data were obtained in separate experiments (data not shown).
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it seems that exposure of H1229 cells to sublethal doses of
CDDP for 24 hours was detrimental for cells in S phase and
caused cells to accumulate in G0-G1. This cytofluorimetric
scenario is mirrored by the results of Western blot
experiments.
Gemcitabine. The cytofluorimetric profile of H1299 cells
after incubation for 24 hours with low doses of gemcitabine
indicates a significant accumulation of cells in S phase
(Table 1; Fig. 6), resulting from a massive (50%; trypan blue
assay) loss of cells in the G0-G1 phase. The cell cycle was
profoundly altered when cells were exposed to gemcitabine
(4 nmol/L) for 8, 12, and 24 hours. At 24 hours, most cells
were synchronized in S phase (Table 1). Synchronization in
S phase was sustained for at least 3 hours after drug
removal and the release of cells into fresh medium (data
not shown). The arrest in S phase was not permanent as
indicated by the fact that surviving cells reverted to the
original (control) profile within 24 hours (data not shown).
Cell accumulation in S phase after 24-hour incubation
with gemcitabine, as shown by cytofluorimetry, was also
consistent with an increase in cyclin A expression
(Fig. 5B, lane 2) and in line with previous observations
(23, 24). In conclusion, treatment for 24 hours of H1299 with
sublethal gemcitabine doses was detrimental for cells in the
G0-G1 phase and induced an accumulation of cells in S
phase. This interpretation is supported by both Western
blot experiments and cytofluorimetric profiles. The altered
expression profiles were totally reverted 24 hours after
drug removal.
Photodynamic Therapy. Photodynamic therapy with
2.5 Ag/mL Photofrin (i.e., at a concentration that does not
present ‘‘dark toxicity’’) induced cellular damage propor-
tional to light fluence. Cell injury went from reversible,
with rapid recovery of cellular functions and growth, to
profound and irreversible. At concentrations f10 Ag/mL
Photofrin, photodynamic therapy causes cell death, apo-
ptosis, or necrosis depending on such factors as light
Figure 4. Effect of single versus combined treatment on the viability of
H1299 cells. Viability was evaluated by the trypan blue assay in control
cells, and cells incubated in the dark with Photofrin (2.5 Ag/mL), after
monotherapy with CDDP (2.5 Amol/L), gemcitabine (Gem ; 4 nmol/L), or
photodynamic therapy (0.54 J/cm2), or combined therapy with 2.5 Amol/L
CDDP and photodynamic therapy (0.54 J/cm2) or 4 nmol/L gemcitabine
and photodynamic therapy (0.54 J/cm2). Columns, average of four
determinations (trypan blue exclusion assay); bars, SD.
Figure 5. Protein expression in cells treated with monotherapy or combined therapy. Protein extracts were analyzed 3 or 24 h after cells were placed in fresh
medium after individual or combined treatments (see Fig. 4). A and C, CDDP; B and D, gemcitabine. Actin was always used as loading control. Further
observations: photodynamic therapy increased the expression of p21 (1–3 h), split the Bcl-XL electrophoretic band in a doublet (see also D), and seemed to
destroyBcl-2 (B). Photodynamic therapy also causeda detectable increase inHSP60andHSP70expression. Indeed, although the expression of actin inC is highly
variable, the expressionofHSP70onphotodynamic therapy (aloneor in combination) is clearly increased,whereas thequestionable fadingofBcl-2 is confirmedby
inspection ofB. Gemcitabine significantly affected cyclin A expression (B). Treatment did not affect Bax and caspase-3 expression (C, B andA, D). Photofrin in
the absence of light (dark effect) did not affect cells as shown by two experiments shown in B andD.
Photofrin/Photodynamic Therapy and Antineoplastic Drugs782
Mol Cancer Ther 2006;5(3). March 2006
fluence, photosensitizer concentration, and cell type (25).
The Photofrin incubation protocol has also been implicated
in the cell death pathway (26). Although we focused on the
effects of a single light dose (0.54 J/cm2), after 16 hours of
incubation with 2.5 Ag/L Photofrin, few H1299 cells
underwent apoptosis (sub-G1; Fig. 6). Indeed, the expres-
sion of Bax (Fig. 5B and C) and caspase-3 (Fig. 5A and D)
was unchanged 3 and 24 hours after photodynamic
therapy. Differently, Bcl-2 expression was significantly
reduced. This coincides with the finding that some photo-
sensitizers induce Bcl-2 degradation (27). Moreover, Hyper-
icin/photodynamic therapy alters the expression and
function of Bcl-2 and delays the onset of apoptosis (28).
Here, we show that also Photofrin/photodynamic therapy
causes Bcl-2 degradation. This degradation, which can only
be inferred from Fig. 5C (lane 3 ; because of the large actin
control variability), clearly emerges in Fig. 5B (i.e., lane 3).
Finally, Photofrin photodynamic therapy caused changes in
the electrophoretic profile of Bcl-XL as indicated by the
disappearance of the faster-migrating Bcl-XL isoform
(Fig. 5A, lane 3 , and D, lane 3). Pc 4 photodynamic therapy
has been shown to damage Bcl-XL isoforms in several
other human cancer cells (29). Although Hanlon et al. (30)
reported a very important increase in the expressions of
HSP60 and HSP70 proteins, they were only modestly, albeit
clearly, enhanced by photodynamic therapy in our con-
ditions (Fig. 5A, B and C, D, respectively). However,
Hanlon et al. used different cell lines as well as much
higher Photofrin concentrations. Indeed, Photofrin concen-
trations higher than 5 Ag/mL are per se highly toxic for
H1299 cells even in the dark.
We used Western blotting to evaluate changes in protein
expression after monotherapy (i.e., individual drugs or
photodynamic therapy) and after combined treatments
(i.e., each drug + photodynamic therapy). It is noteworthy
that with time most protein expression profiles tended to
revert to their original qualitative and quantitative patterns
(Fig. 5A–D). The apparent ‘‘increase’’ in cyclin A expres-
sion (Fig. 5C, lanes 5 –7) may represent an experimental
artifact given the large variability of the actin control. As
stated, the expression of HSP60 and HSP70 proteins was
enhanced after 24 hours albeit to a lesser extent versus
cyclin A (Fig. 5A, C, and D). The cell cycle patterns after
combined therapy (Fig. 6E and F) are not in disagreement
with the protein expression profiling data.
Figure 6 is representative of various experiments con-
cerning the effects of combined treatment. Within 24 hours,
2.5 Amol/L CDDP killedf50% of cells, most of which were
in S phase (Fig. 6B). At variance, photodynamic therapy
(0.54 J/cm2) eliminated mainly G0-G1 cells (Fig. 6D), and
most of the remaining cells were in S phase. In conclusion,
CDDP, at a low concentration, killed cells in S phase, and
surviving cells occurred mainly in G0-G1, a phase in which
cells are susceptible to photodynamic therapy (Table 2A).
Gemcitabine alone, at a concentration as low as 4 nmol/L,
killed f50% of cells (most of which were in G0-G1 phase)
and induced a pronounced accumulation of cells in S phase
(Fig. 6C). It seems that gemcitabine at this concentration
enhances photodynamic therapy cytotoxicity, but to a much
lesser extent than CDDP, and the effect is essentially additive
(Table 2B and C). In controls, 44.2% were in G0-G1, 44.6%
were in S, and 11.2% were in G2-M. After photodynamic
Figure 6. Representative experiments
depicting the cell cycle distribution of
H1299 cells as measured by flow cytometric
analysis of DNA content before (A, controls)
and after treatment with CDDP (B), gemci-
tabine (C), photodynamic therapy alone (D),
or in sequential combination (E and F). In
these cases, cells were analyzed 24 h after
photodynamic therapy. The FACScan soft-
ware assigns apoptotic cells and large cell
debris to sub-G1 phase. Gray histograms,
G0-G1 and G2-M phases; dashed histo-
grams, S phase.
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therapy (0.54 J/cm2) or 24 hours of incubation with CDDP
(2.5 Amol/L) or gemcitabine (4 nmol/L; all conditions that
killf50% of cells), 31.2%, 76.1%, and 18.0% of cells were in
G0-G1, 56.7%, 10.5%, and 82.0% were in S, and 12.1%, 13.4%,
andf0% were in G2-M, respectively. Hence, photodynamic
therapy and gemcitabine preferentially damage cells in
G0-G1, whereas CDDP targets cells in S phase. In conclusion,
it seems that the targeting of cells in different phases results
in an accumulation of death signals caused separately and
independently by photodynamic therapy and a suitable
cytotoxic drug.
Photodynamic therapy is a well-established stand-alone
therapy (9) in which the photosensitizer can be administered
by i.v. injection or applied on the skin and selectively targets
cancer cells. Its effectiveness increases when combined with
other therapeutic measures. Here, we describe a way to
exploit mutual reinforcement of two independent therapeu-
tic modalities: Photofrin/photodynamic therapy and che-
motherapy. Photofrin and porphyrin derivatives, in general,
are the photosensitizers most widely used in photodynamic
therapy. At variance with gemcitabine, which to our
knowledge has never been used with Photofrin/photody-
namic therapy, CDDP has been used in combination with
various photosensitizers, including porphyrin derivatives
(11, 31–35). However, previous studies were mainly
descriptive and were limited to observations about the
effects exerted on cell mortality. No reasons were advanced
to account for the greater efficacy of combined treatment, nor
did those studies report changes in protein expression and
related cell cycle changes. Our study shows that doses of
CDDP or gemcitabine and light/Photofrin that were
partially effective in killing H1299 cells when given singly
were remarkably more effective when used in combination.
These effects span from additive to synergistic. Additivity
occurred with both drugs, but the effect was synergistic
when the drug (CDDP) exerted its activity disjointed, in
terms of cell cycle, from those of photodynamic therapy.
Under the conditions we used, not all metastatic cells were
killed. However, preincubation of H1299 cells with the low
CDDP dose (2.5 Amol/L) followed by their exposure to a
light fluence only 1.5-fold higher (i.e.,f0.80 J/cm2) than that
used in most experiments described herein (f0.54 J/cm2)
resulted in the rapid death of all cells.
In conclusion, selectively localized photosensitizers and
appropriate doses of light combined with low doses of
chemotherapeutic drugs represent a promising treatment
strategy for cancer. In principle, combinations of photody-
namic therapy and drugs would not only destroy cancer
cells more efficiently but would also reduce the noxious
side effects of chemotherapy.
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Photodynamic therapy with indocyanine green complements
and enhances low-dose cisplatin cytotoxicity
in MCF-7 breast cancer cells
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Abstract
Objective: We investigated the effects of photodynamic
therapy (PDT) combined with low-dose chemotherapy on
breast cancer cells. Photodynamic treatment was admin-
istered by irradiating indocyanine green-preloaded MCF-7
cells with an IR diode laser source at 805 nm; cisplatin
was used for chemotherapy. Methods: The dose-response
phenomena associated with the two treatments adminis-
tered individually and together were evaluated with the
following tests: trypan blue dye exclusion, 3-(4,5-dime-
thylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay,
clonogenic survival, thymidine and methionine incorpora-
tion, and insulin-dependent and insulin-independent glu-
cose transport. Results: Viability and metabolic data
demonstrated mutual reinforcement of therapeutic effi-
cacy. However, isobolographic analysis of quantal and
variable data indicated that reinforcement was additive
according to trypan blue data and synergistic according to
MTT data. To investigate the molecular mechanisms un-
derlying alterations in cell proliferation and apoptosis, we
evaluated (by Western blotting) the expression of proteins
Bcl-2, Bax, Bcl-XL, p21, p53, and poly(ADP-ribose) poly-
merase. Photodynamic treatment caused transient selec-
tive destruction of Bcl-2 and up-regulation of Bax. It also
induced apoptosis in a limited fraction of cells (10–12%).
Flow cytometry data showed that PDT killed mostly
G1-phase cells, whereas cisplatin killed mostly S-phase
cells. This disjointed phase-related effect may account
for the favorable effects exerted by combined treatment.
Conclusions: Our findings imply that low doses of cy-
tostatic drugs may be as effective or even more effective
than currently used doses if appropriately combined with
PDT. [Mol Cancer Ther 2004;3(5):537–44]
Introduction
Photodynamic therapy (PDT) is a relatively new and
effective treatment for human tumors (1). It entails local
or systemic administration of a photosensitizer and
subsequent exposure of the neoplastic area to a light of
suitable wavelength. The rationale is that, on exposure to
light, the photosensitizer, which is absorbed by all cells and
selectively retained by malignant tissue (2, 3), is promoted
to an excited state and then, as it decays, induces local
release of cytotoxic reactive oxygen species. Depending on
the experimental conditions and cell sensitivity, the
cytotoxic molecular species resulting from PDT may trigger
cell apoptosis or induce necrosis (4).
The near-IR spectral region is particularly suitable for
PDT because it penetrates deep into tissues without
causing significant heating. To date, the most suitable
IR-photosensitizable molecule is indocyanine green dye
(ICG). In fact, ICG is not toxic, is widely used in humans
as a diagnostic tool in hemodynamics (5, 6), has an
absorption peak between 775 and 810 nm (7, 8), and is a
photosensitizer.
Cisplatin [cis-diammine-dichloroplatinum (II)] is used
in the management of various cancers. By forming adducts
to DNA, cisplatin inhibits DNA replication and chain
elongation, which accounts for its antineoplastic activity. In
clinical practice, cisplatin is often combined with other
chemotherapeutic agents. Synergy between cisplatin and
other chemotherapeutic agents occurs by various path-
ways: increased intracellular drug accumulation, enhanced
binding to DNA, and decreased DNA repair (9).
The MCF-7 cell line was established 30 years ago from
the pleural effusion of a patient with a breast carcinoma
(10). These malignant cells have functional p53, lack
caspase-3 activity, maintain a functionally intact estrogen
receptor, and have constitutively high levels of Bcl-2, a
protein endowed with cytostatic and antiapoptotic activi-
ties (11, 12). The latter two features are probably closely
related because, as we have recently shown, the coding
sequence of the bcl-2 gene includes a functioning estrogen-
responsive element (13).
MCF-7 cells are remarkably resistant to various treat-
ments including cisplatin and some types of PDT but not to
tumor necrosis factor or staurosporin (14). However, the
cells become sensitive to cisplatinum on p53 disruption
(15). In contrast, parental MCF-7 cells and p53-abrogated
cells are equally sensitive to photofrin/PDT (16).
In an attempt to identify treatment combinations in
which the dose of the toxic compound could be decreased
without reducing efficacy, we examined the effects of
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moderately toxic doses of cisplatin and ICG/PDT, admin-
istered separately and together, on various metabolic and
proliferative parameters of MCF-7 cells. We also describe
changes in the expression profile of some proteins in-
volved in the control of the cellular proliferative status
and apoptosis.
Materials andMethods
Cells
Human breast cancer MCF-7 cells were grown at 37jC in
a humidified atmosphere (95% air and 5% CO2), DMEM
supplemented with phenol red, L-glutamine (2 mM),
penicillin (100 units/ml), streptomycin (100 Ag/ml), genta-
micin (50 Ag/ml), and 10% FCS. Fresh medium was
provided every 3 days.
Laser Source
The laser source was a diode array laser from Quanta
System (Milan, Italy) emitting at 805 nm. The nominal
output energy (continuous wave) was 0.65 W. The laser
was equipped with an adjustable (0.1 s) time shutter.
Photosensitizer and Photosensitization
The ICG (Mr = 775.0) preparation (Sigma Chemical Co.,
St. Louis, MO) was iodide free, unlike the ICG preparations
used for most previous studies (7, 17). The ICG stock
solution was obtained by dissolving the deep green powder
(f1 mg/ml) in 100 mM sodium phosphate (pH 7.2). Before
measurements, appropriate aliquots of this solution were
diluted to the desired concentration. The purity of the com-
mercial product was checked by isocratic high-performance
liquid chromatography in 10 mM sodium phosphate in
47% acetonitrile, 3% methanol using a C18 reverse-phase
column equipped with a UV detector set at 230 nm.
Aqueous ICG samples at various concentrations (between
10 and 400 AM) were analyzed by high-performance liquid
chromatography immediately after their preparation and
after extensive irradiation (>1000 J cm2). The resulting
chromatograms did not differ from that of nonirradiated
ICG, except for a significant decrease in the relative height
(and areas) of the ICG peaks, which indicates extensive
photobleaching of the dye.
Photosensitization experiments were performed with
MCF-7 cells incubated in 20 AM ICG for 24 h. Because of
the low concentration of ICG used, we did not measure
uptake of the dye by MCF-7 cells in these conditions.
However, the ICG uptake in keratinocytes under similar
experimental conditions was about 3–5 nmol/105 cells (17).
Plates were washed twice with ICG-free medium and
positioned under the laser beam at the appropriate dis-
tance. The temperature of plates during irradiation was
controlled by their partial immersion in a water bath heated
at 35jC. Except for the dose-response curves shown in
Fig. 1, cells were routinely irradiated with light doses of
25 J cm2. After exposure(s), cells (normally quadrupli-
cates) were incubated in the dark at 37jC for an additional
5 h (or >10 h in some cases) before further analysis.
SampleTreatment Schedules
All experiments reported herein included several
controls (i.e., untreated cells, ICG-loaded but not light-
sensitized cells, and cells exposed to light in the ab-
sence of ICG). The various parameters evaluated under
these conditions did not differ and are not reported
herein.
CellViability, Cytotoxicity, and Survival Assays
Trypan Blue Dye Exclusion Assay. Cell viability after
treatment (irradiation, cisplatin, or both) was determined
by the trypan blue dye exclusion test 5 h after each
treatment (unless indicated otherwise). All assays were
performed in quadruplicate and results are reported as the
mean F SD.
3-(4,5-Dimethylthiazol)-2,5-Diphenyltetrazolium Bro-
mide Assay. Cell viability after each treatment (irradiation,
cisplatin, or both) was determined by the 3-(4,5-dime-
thylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay
(18). MCF-7 cells (2  104 cells/0.2 ml) were seeded in 96-
well plates and kept in the incubator at 37jC overnight.
Cells were then treated with ICG alone, cisplatin alone, or
ICG plus cisplatin and incubated for a further 24 h. After
incubation, cells containing ICG were irradiated with a
fluence of 25 J cm2. Five hours later, cells were washed,
collected in tubes, and centrifuged at 1000 rpm for 5 min.
Supernatants were removed and the cells were resus-
pended in ICG-free medium. Control cells were processed
in the same way. A MTT stock solution was made by
dissolving the crystals in a phenol red-free culture medium
to a final concentration of 0.5 mg/ml. Typically, 50 Al of
this solution were added to each well containing sus-
pended cells in 200 Al of medium. After an additional 4 h
incubation at 37jC, cells were collected by aspiration and
Figure 1. Effect of three doses of ICG photosensitization at 805 nm on
MCF-7 cells. Five hours after each irradiation, cell viability was assessed
by the trypan blue exclusion test. Points, average of four determinations;
bars, SD. Combination treatments were performed at a light fluence of
25 J cm2 and an ICG concentration of 20 AM (hatched line ).
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centrifuged at 1500 rpm for 7 min. The converted dye was
extracted from the supernatant obtained by adding acidic
(0.1 M HCl) isopropanol to the pelleted cells. Absorbance of
the samples, read with a Titertek-Multiscan photometer
(Huntsville, AL) equipped with a 532 nm filter, of
converted dye in stimulated cells versus untreated controls
is called MCF-7 viability. Quadruplicate samples were used
in each experiment.
Clonogenic Survival Assay. The assay was performed
exactly as described by Theodossiu et al. (19). Cells were
seeded in 100 mm Petri dishes at low density (f3  104/
dish) and left to adhere for 24 h in a standard medium.
ICG (20 AM) and/or cisplatin (8 AM) were added where
appropriate. Twenty-four hours later, samples intended for
PDT, alone or in combination, were irradiated (fluence of
25 J cm2).
After irradiation, cells were washed, immediately trypsi-
nized, resuspended in single-cell suspension, and plated
for the determination of macroscopic colony formation.
After 6 days of growth, colonies were fixed with a 3:1
mixture of methanol/acetic acid and stained with crystal
violet. Only colonies constituted by more than 50 cells were
scored (19). Two separate experiments were performed
using duplicate samples.
Flow Cytometry
Plates containing 5  105 MCF-7 cells were incubated for
24 h at 37jC in 2 ml complete medium (controls) or medium
supplemented with ICG (20 AM), cisplatin (8 AM), or both
(ICG and cisplatin). Photodynamic treatment of cells was
performed as reported under Photosensitizer and Photosen-
sitization. Cells were detached by trypsinization from 10 cm
plates, suspended in serum-rich medium, centrifuged,
washed twice with 1 ml PBS, and resuspended for storage
(4jC) in absolute ethanol. Before analysis, fixed cells were
washed twice, centrifuged, and resupended in 1 ml PBS
containing 5 Ag RNase and 100 Ag propidium iodide.
Samples were stored in the dark for 20 min at room tem-
perature before final readings. The cellular orange fluores-
cence of propidium iodide was detected on a linear scale
using a flow cytometer (FACScan, Becton Dickinson, Moun-
tain View, CA) equipped with an excitation laser line at
488 nm. At least 20,000 eventswere collected for each sample.
The cell cycle was examined 5 h after each single or com-
bined treatment. Four separate experiments were performed.
Thymidine Incorporation
Thymidine incorporation experiments were performed
in 24-well plates according to Love-Schimenti et al. (20)
with minor modifications. In brief, cells (3  104 cells/well)
were incubated at 37jC in 2 ml complete medium (controls)
or medium supplement with ICG (20 AM), cisplatin (8 AM),
or both. All samples were run in triplicate. After 24 h
incubation, each well was washed with 1 ml warm
medium. ICG-loaded cells were then irradiated at
25 J cm2. After irradiation, the medium was replaced (all
samples) with fresh culture medium containing labeled
[3H]thymidine (0.5 ACi/ml; Amersham, Buckinghamshire,
UK). After 5 h at 37jC, incorporation was blocked by
extensive washing with warm serum-free medium. NaOH
(0.1 M) was added to all wells (1 ml) and the plates were left
at 37jC for 1 h under constant agitation. Solutions (100 Al)
were used to measure the protein content (21) and the
remainder was used to measure the incorporated thymi-
dine with the semiautomatic Harvester 96 (Skatron Instru-
ments, Lier, Norway). Thymidine counts were expressed
as a fraction of counts found in controls.
Methionine Incorporation
We used six-well plates for methionine incorporation
experiments as described by Consiglio et al. (22). Cells
(105 cell/well) were incubated at 37jC in 2 ml complete
medium (controls) or medium supplemented with ICG
(20 AM), cisplatin (8 AM), or both (ICG and cisplatin). All
samples were run in triplicate. After 24 h incubation under
these conditions, each well was washed with 1 ml warm
medium and irradiated at 25 J cm2 (ICG-loaded cells
only). Four hours later, the medium of each well was
replaced with 1 ml medium containing 30 ACi [35S]methi-
onine (specific activity 1000 Ci/mmol; Amersham, United
Kingdom). After 60 min, labeling was terminated by three
consecutive washings with 1 ml cold PBS. Cells were fi-
nally scraped and lysed by keeping them for 15 min on
ice with 0.45 ml lysis buffer consisting of 137 mM NaCl,
4 mM KCl, 1 mM MgCl2, 1% Triton X-100, 0.1% BSA and
protease inhibitors, 50 Ag/ml leupeptin, and 50 Ag/ml
aprotinin. Aliquots (100 Al) of cell lysates were precipitated
in triplicate on GFC Whatman (Springfield Mill, UK) filters
by soaking them in 10% trichloroacetic acid (TCA) on ice
for 10 min. Filters were washed thrice for 10 min in 5%
TCA and then rinsed twice in 95% ethanol and acetone.
Finally, filters were dried at 60jC and counted in a
Beckman (Fullerton, CA) liquid scintillator.
Increasing the time of lysis from 30 min to 2 h did not
affect the TCA-precipitable counts. Aliquots of 100 Al were
used to measure protein contents according to the pro-
cedure of Bradford (21).
Deoxyglucose Uptake
Glucose uptake was determined according to Singh et al.
(23). Twenty-four plates (3.5 cm) containing MCF-7 cells
(2  105 cells/well) were incubated for 24 h at 37jC in 2 ml
complete medium (controls) or medium supplemented
with ICG (20 AM), cisplatin (8 AM), or both. The cells were
then washed with fresh medium. The plates intended for
PDT (alone or in combination) were irradiated as usual.
Five hours later, all cells were washed thrice again with
PBS and divided into two groups of 12 plates each (four
samples, each sample in triplicate). The two groups of
12 plates each (i.e., three controls, three plates treated with
cisplatin alone, three plates treated with ICG/PDT alone,
and three plates treated with cisplatin and ICG/PDT) were
incubated for 30 min at 37jC in a buffer containing 1 ACi
[14C]deoxyglucose (specific activity 200 ACi/ml) in the
absence or presence of 1 AM insulin. Uptake was terminated
in all plates by extensively washing cells with ice-cold PBS.
Cell monolayers were finally solubilized with 1 ml 0.01%
Triton X-100 in 0.01 M NaOH. Aliquots of 100 Al served for
protein determination (21) and the rest was used for liquid
scintillation counting.
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Isobolographic Analysis
Isobolograms were constructed according to a ‘‘fixed
dose method’’ (24, 25). Firstly, the responses in a fraction x
of the cells were evaluated after treatment with PDT or
cisplatin. A fraction corresponding to 75% was found to
be suitable and is called ED75. Cells were then assigned
to receive treatment consisting of a fixed dose of cisplatin
(8 AM) combined with PDT of increasing potency by
varying light fluence from 0 to 60 J cm2, the ICG
concentration remaining fixed at 20 AM. The aim of this
analysis was to ascertain experimentally the light dose
necessary to attain the prefixed effect in the presence of
the prefixed concentration of cisplatin.
In a typical isobologram, the EDx, computed by the
individual dose-response curves, was plotted on the
vertical and horizontal axes, respectively. The theoretical
dose-additive line, including its 95% fiducial limits (calcu-
lated by the SE multiplied by 1.96), was attained by joining
the two EDx of choice. If the experimental EDx of the
combination is within the boundary of the dose-additive
line and the confidence interval (i.e., the experimental point
is nearly coincident with the theoretical point), then the
specific combination of PTD with a fixed concentration
of cisplatin exerts a dose-additive effect. The effect is
synergistic if the experimental point and theoretical point
are below the boundaries and antagonistic if they are above
the boundaries.
PAGE andWestern Blotting
Polyacrylamide gels (15% or 7.5%) were prepared essen-
tially as described by Laemmli (26). Proteins separated on
the polyacrylamide gels were blotted onto nitrocellulose
filters (Hybond-C pure; Amersham, Milan, Italy) and
immunorevealed with specific primary monoclonal anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA). Filters
were washed and treated with horseradish peroxidase-
linked antibodies and the blots were revealed autoradio-
graphically with enhanced chemiluminescence detection
reagents (Amersham, Milan, Italy). The entire procedure
has been described elsewhere (27). Blots were reprobed
with h-actin antibody as loading control. Autoradiographs
were scanned with a Discover Pharmacia Scanner equip-
ped with a Sun Spark Classic Workstation and appropriate
software (pdi, RFL print, version 2; Oakwood, Huntington
Station, NY).
Results and Discussion
We have evaluated if treatment with ICG/PDT plus
cisplatin results in an effective outcome (additive or even
synergistic) so that the dose of the two components or at
least of the most toxic one (i.e., cisplatin) can be reduced.
We analyzed (a) the response of ICG-treated cells to
increasing light doses and (b) the response of MCF-7 cells
to cisplatin administered alone (at increasing concentra-
tions) or combined with ICG/PDT. In all the combined
treatment experiments, we used a low cisplatin concentra-
tion (8 AM) and rather mild PDT conditions (20 AM ICG,
light fluence of 25 J cm2).
IndividualTreatments
Dose-Response Effects of ICG/PDT on Cell Viability. As
shown in Fig. 1 (upper panel), both ICG concentration and
light dose affected the magnitude of cell injury. At a fluence
of 50 J cm2, about 30% of cells survived exposure to 20 AM
ICG, much less survived exposure to 25 AM ICG, and no
cells survived exposure to 50 AM ICG. To ascertain the effect
of combined treatment, we administered PDT at sublethal
doses using an ICG concentration of 20 AM. Figure 1 (lower
panel) shows the dose-response curves obtained with this
ICG concentration. Apparently, the ED75 as measured by
MTT assay and the trypan blue exclusion test are not su-
perimposable because they span from f47 to f52 J cm2,
respectively. Except where specifically indicated, all experi-
ments reported hereafter were conducted with cells pre-
loaded with 20 AM ICG and a light fluence of 25 J cm2.
Dose-Response Effects of ICG/PDT on Protein Expres-
sion. To test whether ICG/PDT altered the expression of
proteins related to cell death, we measured the expression
of proteins Bcl-2, Bax, Bcl-XL, p21, poly(ADP-ribose) poly-
merase (PARP), and p53 by Western blot analysis. The
analyses were performed 5 and >10 h after irradiation with
either 15 or 25 AM ICG and two different fluences (i.e., 15 or
25 J cm2). Figure 2 shows that Bcl-2 expression decreased
while Bax expression increased as the fluence increased
from 15 to 25 J cm2. PARP cleavage is clearly visible only
at most effective conditions. Such increase in PDT efficacy
caused also an increase in the expression of p21 and p53
proteins; at variance, no changes were observed in the
expression of Bcl-XL. Indeed, time course experiments
demonstrated that the expression profiles of Bcl-2, Bax, and
other proteins analyzed returned to basal levels in about
10 h (data not shown). Possibly, the PDT-driven Bcl-2
disruption transiently deranged the equilibrium between
Figure 2. Expression of various proteins at different ICG concentrations
and light fluence rates. Proteins were extracted 5 h after PDT. Note the
effects on Bcl-2 (fading), Bax (increase), and PARP (fragmentation) at
most drastic conditions.
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proapoptotic and antiapoptotic proteins, thereby resulting
in apoptosis of a small fraction of cells. The PARP
fragmentation shown in Fig. 2 was unexpected because
MCF-7 cells do not express caspase-3, the activation of
which is a prerequisite for PARP degradation. However,
apoptotic pathways that involve caspases (caspase-6 and/
or caspase-7) other than caspase-3 have been described in
MCF-7 cells (28, 29). MCF-7 human breast cancer cells are
p53 positive and highly resistant to many harmful agents.
The scarce sensitivity of MCF-7 cells to cisplatin-induced
apoptosis has been ascribed to a functioning p53 because
apoptosis was greater in cisplatin-treated cells in which p53
was abrogated (15). The effect of the antiapoptotic protein
Bcl-2, the transcription of which is up-regulated in MCF-7
cells via two estrogen-responsive elements (13), may be an
additional protective factor. However, apoptosis could not
be elicited in these cells by photofrin/PDT even on p53
abrogation (16). Here, we report a similar observation with
ICG/PDT. Although p53 and p21 expression was enhanced
in relation to photosensitizer concentration and light dose
(Fig. 2), only a limited fraction of cells may undergo
apoptosis. The photodynamic destruction of the Bcl-2
protein, accompanied by Bax up-regulation, has already
been reported in MCF-7 cells (30) although with a different
photosensitizer (phthalocyanine Pc 4). Thus, Bcl-2 may also
be a preferential target of ICG/PDT, and PDT-induced
damage to Bcl-2 may explain the death of a fraction (10–
12%) of MCF-7 cells. It is noteworthy that Bax expression
increased as Bcl-2 expression declined. At present, we are
unable to explain this increase. It was interesting to observe
PARP fragmentation in the MCF-7 cells that lacked
caspase-3; it is conceivable that ICG/PDT would trigger
greater apoptosis in caspase-3-positive cells. This has
indeed been shown in human retinal pigment epithelial
cells (31) and in a human leukemic cell strain from a
histiocytic lymphoma (8).
Dose-Response Effects of Cisplatin. Figure 3 shows the
results of the trypan blue dye exclusion and MTT assays of
cells treated with increasing concentrations of cisplatin
(1.5–20.0 AM). The trypan blue assay reveals cells with
intact membrane; the MTT assay is a measure of the re-
ductive potential of mitochondrial enzymes. The cisplatin
dose required to kill 75% of cells (ED75) was near 20 AM
according to the trypan blue exclusion test and 17 AM
according to MTT data. With 8.0 AM cisplatin, almost
50–60% of cells were viable 5 h after withdrawal of the
chemotherapeutic agent. Consequently, we used this sub-
lethal cisplatin dose in the combined experiments re-
ported hereafter.
CombinedTreatments
In the experiments of combined treatment, we used 8 AM
cisplatin and 20 AM ICG at a light fluence of 25 J cm2.
Administered singly, these treatments were not lethal for
MCF-7 cells. As shown in Fig. 4, cell viability as assessed by
trypan blue assay (membrane integrity) was reduced by a
factor of f1.6 with 8 AM cisplatin, f2.0 with ICG/PDT
(20 AM/25 J cm2), and f4 with combined treatment
(cisplatin plus ICG/PDT) as compared with untreated
controls. Similar results were obtained with the clonogenic
assay (same figure), which measures the ability of each cell
in the culture to maintain all the functions needed to di-
vide and form a colony. The MTT assay gave somewhat
different results: the reduction in cell viability was much
greater with cisplatin plus PDT (f10-fold) than with
the two treatments administered separately (f1.5- and
f2.0-fold, respectively).
Finally, we found that ICG/PDT and cisplatin target
different phases of the cell cycle. In fact, only about 40%
of the G1 cell population survived ICG/PDT versus 65% of
control cells. Differently, after cisplatin treatment, 85% of
the surviving cells accumulated in the G1 phase. This
finding coincides with the observation that cisplatin
induces cell cycle arrest and death in the S-G2 phase (32).
The cell cycle-related effect of ICG/PDT and cisplatin on
MCF-7 cells ensures continuous apoptotic coverage
throughout the cell cycle, thereby potentiating the overall
lethal output.
Individual and CombinedTreatments: Effects on Cell
Metabolism
DNA Synthesis. The impairment of cellular function
may be also measured by evaluating the ability of cells to
incorporate thymidine into nuclear DNA. We assessed
DNA synthesis in control and treated cells by measuring
incorporation of thymidine into DNA. As expected, both
chemotherapy and PDT significantly inhibited DNA
synthesis. The residual capacity of cells to incorporate
thymidine (Fig. 5, hatched bars) into DNA after individual
treatments was reduced by a factor off1.3 in the presence
of 8 AM cisplatin and by a factor of f2 with ICG/PDT. As
compared with untreated controls, DNA synthesis was
reduced by f10-fold with ICG/PDT plus cisplatin.
De Novo Synthesis of Proteins. To evaluate whether
protein synthesis was altered in the cells treated with ICG/
PDT and cisplatin, we measured the percentage change in
Figure 3. Effect of increasing concentrations of cisplatin (15–15 AM) on
MCF-7 viability. Cells were incubated at the indicated cisplatin concen-
trations for 24 h. Cells were then washed with complete medium and left
to stand for 5 h. Cell viability was measured by the trypan blue exclusion
test (open circles) and MTT assay (filled squares ). Points, average of four
determinations; bars, SD.
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labeled methionine incorporated into neosynthesized pro-
teins in normally growing cells (controls), in cells exposed
for 24 h to cisplatin (8 AM), in cells irradiated at a fluence
of 25 J cm2 after 24 h incubation in a medium containing
ICG (20 AM), and in cells exposed to both treatments (Fig. 5,
filled bars). As expected, both chemotherapy and PDT
significantly inhibited protein synthesis. The residual ca-
pacity of viable cells to incorporate methionine into their
proteins after individual treatments was reduced by factors
off1.6 andf2.7, respectively, with respect to controls. On
combined treatment, the capacity of cells to incorporate
methionine approached 0.
Glucose Uptake. Glucose uptake and metabolism are
increased in most cancer cells. It is well known that ma-
lignant cancer cells are unable to store glucose and depend
on constant refurbishment to meet their energy require-
ments (33). It is also known that GLUT-1 expression is
enhanced in malignant cells (34). Therefore, inhibition of
deoxyglucose uptake, either basal or insulin stimulated,
may give a measure of cell fitness. We found that single
and combined treatments caused a significant reduction
in (deoxy)glucose uptake (Fig. 6). The decrease paralleled
the decrease in thymidine and methionine incorporation
on similar treatments. Glucose transport was increased by
25–30% in control insulin-treated MCF-7 cells (Fig. 6).
Both individual and combined treatment inhibited this
response to insulin. The changes in DNA synthesis, protein
synthesis, and glucose transport in surviving cells evalu-
ated 5 h after treatment reflected the general trend of
changes revealed by cell viability assays; moreover, they
were very similar to the changes revealed by the MTT
assay.
Isobolographic Assessment of the Effects of Combi-
nations of PDTand Cisplatin
The effects of combined treatments may be evaluated by
analyzing dose-response experimental data isobolographi-
cally. Dose-response phenomena can have either quantal or
measurement values. Quantal responses are framed by
questions about what fraction of exposed organisms
showed the index response. Measurement responses are
those with magnitude that usually increases or decreases as
a continuous variable in response to mounting stimuli. In
this regard, we constructed isobolograms with quantal data
(trypan blue assay; Fig. 7, upper panel) and variable data
(MTT assay; Fig. 7, lower panel). Dose-response curves were
assessed by evaluating cell viability with the trypan blue or
MTT assay at fixed cisplatin concentration (8 AM) followed
by irradiation with fluences between 0 and 60 J cm2 (20 AM
ICG).
Based on MTT data, the fluence rate required to obtain
75% lethality (ED75) was lower than that indicated by
trypan blue assay data. In fact, as shown in Fig. 7, MTT was
better than trypan blue in detecting cell viability. The first
isobologram (trypan blue data) shows that PDT plus
cisplatin had an additive effect, whereas the second
Figure 4. Viability of MCF-7 cells was estimated after single (8 AM
cisplatin or 20 AM ICG/25 J cm2) or combined (8 AM cisplatin and 20 AM
ICG/25 J cm2) treatments. Viability was measured with the trypan blue
assay exclusion test, colony-forming assay (quantal responses), or MTT
assay (variable response). Columns, average of four (trypan blue
exclusion test and MTT assay) or two (colony-forming assay) determi-
nations; bars, SD.
Figure 5. [3H]Thymidine (black bars ) and [35S]methionine (gray bars )
incorporation into MCF-7 cells after single (8 AM cisplatin or 20 AM ICG/25
J cm2) and combined (8 AM cisplatin and 20 AM ICG/25 J cm2)
treatments. Columns, average of three determinations; bars, SD.
Figure 6. Basal versus insulin-stimulated [14C]deoxyglucose incorpora-
tion into MCF-7 cells after single (8 AM cisplatin or 20 AM ICG/25 J cm2)
and combined (8 AM cisplatin and 20 AM ICG/25 J cm2) treatments.
Columns, average of three determinations; bars, SD.
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isobologram (MTT data) shows that it had a synergistic
effect. This observation is in line with the possibility that
metabolic impairment of cells (measured by MTT), which
occurs well before cells are irreversibly damaged (detected
by trypan blue), is a more sensitive indicator of cell fitness.
Although the response to the various treatments, as
assessed by trypan blue and MTT data, was similar, the
magnitude of change differed between the two techniques.
In fact, the response was additive based on trypan blue
data and quasi-synergistic based on MTT data. In both
cases, combined treatment resulted in mutual reinforce-
ment of destructive efficacy. This observation is supported
by the cell cycle analysis of cells exposed to PDT, cells
incubated with low-dose cisplatin, and cells exposed to
PDT after incubation with low-dose cisplatin. In fact,
cisplatin killed mostly S-phase cells, whereas ICG/PDT
killed mostly G1-phase cells. Only a small fraction of cells
survived combined treatment, although cisplatin and ICG/
PDT administered singly would kill only a limited number
of cells. Obviously, preincubation of MCF-7 cells with the
usual cisplatin dose (8 AM) followed by their exposure to
higher light fluences (e.g., 40 J cm2) results in the rapid
death of all cells. Therefore, in principle, a combination
consisting of a low dose of cisplatin and appropriately
adjusted ICG/PDT dosage (i.e., higher light fluence and/or
photosensitizer concentration) would be effective. This
strategy was among those listed by Dolmans et al. (35) in
their review of PDT for cancer treatment. Our study
supports the validity of this strategy and provides a clinical
perspective. In fact, it appears from our data that the
adverse effects of chemotherapy can be partially abated
without reducing the efficacy of treatment. Obviously, this
hypothesis should be tested in in vivo models before
being applied in human therapy.
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